

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number
WO 03/099312 A1

- (51) International Patent Classification⁷: **A61K 38/00**, 39/00 // C07K 15/52, 14/735, 16/00
- (74) Agent: **STRÖM & GULLIKSSON IP AB**; Sjöporten 4, S-417 64 Göteborg (SE).
- (21) International Application Number: PCT/SE03/00869
- (22) International Filing Date: 27 May 2003 (27.05.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0201563-4 27 May 2002 (27.05.2002) SE
60/411,517 18 September 2002 (18.09.2002) US
- (71) Applicant (*for all designated States except US*):
ÖSTERGÖTLANDS LÄNS LANDSTING [SE/SE];
Landstingets Kansli, St. Larsgatan 49 B, S-581 91
Linköping (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **HÅKANSSON, Leif** [SE/SE]; Vikingstad Prästgård, S-590 51 Vikingstad (SE). **HÅKANSSON, Annika** [SE/SE]; Vikingstad Prästgård, S-590 51 Vikingstad (SE). **CLINCHY, Birgitta** [SE/SE]; Kanalvägen 34, S-590 72 Ljungsbro (SE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR DETERMINING IMMUNE SYSTEM AFFECTING COMPOUNDS

(57) Abstract: The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys-regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer, a method for analysing dys-regulatory mechanism controlling substances, kit for such analysis, use of certain compounds for preparing pharmaceutical preparations, and pharmaceutical preparations.

WO 03/099312 A1

TITLE**METHOD FOR DETERMINING IMMUNE SYSTEM AFFECTING COMPOUNDS****DESCRIPTION**

5

TECHNICAL FIELD

The present invention relates to method for treating cancer, method for determining immunoregulatory substances, kit for carrying out said determination, use of certain compounds for preparation of pharmaceutical compositions, as well as
10 pharmaceutical compositions.

Background of the invention

Evidence of the occurrence of immunogenic tumours among a majority of different types of human cancers is increasing, e.g., specific cytotoxic T-lymphocytes, CTLs,
15 are found in the blood of cancer patients, antibodies against tumour associated antigens have been identified, inflammatory cells are infiltrating the tumours, there is often a correlation between these cells and prognosis or response to immunotherapy and an immune mediated anti-tumour reactivity has been demonstrated after therapy.

20

The function of immune cells in cancer patients is, however, often impaired. Generally this is more pronounced in tumour infiltrating mononuclear cells (Vose et al., 1977), TIMC, than in cells obtained from peripheral blood. It has for example repeatedly been demonstrated that the proliferative response to mitogens, such as
25 phytohemagglutinin (PHA) or concanavalin A (ConA), is inhibited, natural killer cell (NK-cell) activity and cytotoxic activity of CTLs are reduced as is the maturation and function of dendritic cells and the immune balance seems to be directed to a T-helper 2 situation (Pawelec et al. 2000).

30 Immunosuppression of TIMC can, however, at least to some extent be overcome, either by washing, preincubation before stimulation, or culturing in interleukin-2. Amazingly, the down-regulation of the immune system, which relates to cancer, does not result in a seriously increased incidence of infectious diseases in these patients.

35 The demonstration of concomitant immunity shows the existence of regional immunosuppression in the absence of systemic suppression, indicating a regional - systemic gradient of immunosuppression (North, 1985). Systemic

immunosuppression can thus be regarded as a systemic dissemination, or "spill-over" of intra-tumoural suppression.

Extracts or supernatants from tumours are often immunosuppressive (Sulitzeanu, 1993). Several factors have been suggested to mediate this suppression, e.g., TGF- β , PGE₂, IL-10, IL-4 and others, either being produced by the tumour cells as such or by tumour-infiltrating lymphocytes (TIL) or tumour associated macrophages (TAM) (e.g. Ménétrier-Caux et al., 1999; Heimdal et al., 2000; Heimdal et al., 2001). However, no fundamental mechanism has been identified so far (Mocellin, 2001).

The immunosuppression of cancer patients described above often involves an ongoing systemic, chronic inflammation with an increased production of cytokines, in particular IL-6 and TNF- α seems to be important mediators in this process. This results in a paraneoplastic syndrome with a poor performance status - impaired general condition, which is characterized by anorexia, fatigue, subfebrility and distortion of various biochemical laboratory parameters, e.g., low haemoglobin concentration, high numbers of platelets, increased numbers of blood monocytes, increased concentration of acute phase reactants, increased c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and other factors (Barton, 2001; Blay et al., 1992; Blay et al., 1997; Gadducci et al., 2001; Walther et al., 1998). This condition is correlated to the tumour burden of the patient, being worse in more advanced disease. In the clinical situation, attempts are often made to ameliorate the poor general condition of these patients by corticosteroid treatment.

Chronic inflammatory reactions in cancer patients often result in a poor response to the immunotherapy (Blay et al. 1992; Deehan et al., 1994; Lissoni et al., 1999; Tartour et al., 1996). There are some animal and human reports on the importance of the immune status of tumour bearers for response to cytotoxic treatment/chemotherapy or radiotherapy. (Goldin et al., 1980; Milas et al., 2001)

Immunostimulatory treatment of the dysregulated immune system of cancer patients might be counter-productive. If the immune system in cancer is directed to down-regulation of the chronic inflammatory reaction there is a risk that further therapeutic immunostimulation will enhance the immunosuppression and thereby further down-regulate the immune reactivity against the tumour cells. The strategy should therefore be to eliminate mediators of immunosuppression before the immune system is stimulated.

In developing immunotherapeutic strategies in cancer several critical steps, of major importance for initiation and maintenance of immune mediated anti-tumour reactivity, have to be considered.

- 5 For initiation of an immune response the tumour has to be recognised as non-self. The initial induction of an immune response to tumour associated antigens takes place at an early stage of the malignant disease while the tumour burden is still reasonably small and tumour related immunosuppressive mechanisms are not yet activated. In this situation the immune reactivity to the tumour is beneficial and
10 control the malignant growth for some time.

In order to get an immune response a proper interaction between antigen presenting cells (APCs) and lymphocytes has to take place with a well-orchestrated production of cytokines and expression/interaction of co-stimulatory molecules.

- 15 In cancer patients with macroscopic, progressive tumour a different situation prevails. The anti-tumour immune reactivity has been suppressed. In a small subset of patients the immunostimulatory therapeutic strategies, which are available, e.g., interferons, interleukins, vaccination, can overcome this immunosuppression, which
20 results in objective tumour regression in only about 10-15 percent of the patients and short-lasting minor regressions in some more. The poor efficacy of such treatment strategy depends on the occurrence of non-immunogenic tumours, serious immunosuppression (which can not be overcome by current therapeutic methods) and down-regulation of the immune reactivity during immunotherapy. Tumour
25 related suppressor substances might interfere with these mechanisms during development of immunosuppression. Immune mediated anti-tumour reactivity also seems to be down regulated via interaction with FcR, in particular FcγR.

Tumour related immunosuppression takes place at four levels: Activation, recruitment of effector cells to the tumour, migration of these cells from stromal areas close to the tumour cells and cytotoxic activity.

- 5 Mechanisms by which malignant tumours can down-regulate the immune system are
- tumour derived non-immunogenic substances with suppressor activity;
 - well-characterized immunomodulating substances, cytokines, e.g., transforming growth factor beta (TGF- β), IL-10, as well as PGE₂,
 - tumour associated antigen (TAA) resulting in antigenic overload, production
10 of antibody and immunocomplex (IC);
 - serum blocking factors, which are probably related to immune complexes, cross-linking Fc receptor (Fc γ R);
 - proteolytic fragments from tumour substances, e.g., extracellular matrix (ECM);
 - 15 - T-helper 1/ T helper 2 (Th1/Th2) balance

Stimulation of the inhibited immune reactivity to the tumour can be achieved using several therapeutic strategies. However, several function parameters are down-regulated during the treatment, particularly in tumour areas with the most
20 pronounced regressive changes.

It would thus be of great importance in the treatment of cancer patients to identify the mechanisms by which the immune system is dys-regulated and to develop proper
25 diagnostic tests of this condition. The ultimate goal is then, based on these tests to find measures to treat, eliminate the immunosuppression, and thereby improve the general condition of cancer patients and increase the therapeutic efficacy in cancer.

Summary of the present invention

30 It has been found that efficacy and possibility of therapeutic treatment of cancer can be increased, whereby any dysregulatory mechanism of the production of immunoregulatory substances, is therapeutically controlled to minimise pathological production of such immunoregulatory substances, to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer and the chronic inflammatory reaction in cancer patients which latter reaction plays an important role
35 in cancer therapy.

The object of the present invention is thus to obtain a method for increasing the possibility of treating cancer, a method for determining factor(-s) related to

2
Wp

prognosis and allowing prediction and monitoring therapy of cancer, and a kit for determining such factor(-s), use of substances to prepare pharmaceutical compositions, as well as pharmaceutical compositions.

5 Description of the present invention

It has now surprisingly been found a method for increasing efficacy and possibility of therapeutic treatment of cancer, wherein any regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is therapeutically controlled to
10 minimise pathological production of such immunosuppressive immunoregulatory substances or to stimulate the production of immunosupportive immunoregulatory substances to enhance the performance status of a patient and/or to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer.

15 According to a preferred embodiment any dysregulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR modulation by administering a therapeutically effective amount of a FcR modulating
20 agent.

According to another preferred embodiment any dysregulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from
25 cancer is modulated by therapeutically treating the patient to provide a FcR/Fc γ R modulation by administering a therapeutically effective amount of a FcR/Fc γ R blocking agent.

According to another preferred embodiment any dysregulatory mechanism of
30 immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR/Fc γ R modulation by administering a therapeutically effective amount of a FcR/Fc γ R cross-linking agent.

35 According to another preferred embodiment blocking or cross-linking of FcR is carried out using a therapeutically active amount of at least one immunoglobulin, FcR

antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR.

- 5 According to another preferred embodiment at least one FcR-modulating substance minimising production of interleukin-1 receptor antagonist is administered in a therapeutically effective amount.

According to another preferred embodiment wherein the modulation is carried out by blocking FcR by administering F(ab), or F(ab')₂-fragments.

10

According to another preferred embodiment the modulating substance is a soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins.

- 15 According to another preferred embodiment FcγR I, FcγR II and/or FcγR III is modulated to stimulate IL-2 stimulation of clonal expansion of lymphocytes.

- 20 According to another preferred embodiment any compound blocking the production or biological activity of a factor inducing pathological production of any dysregulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, production, is administered in a therapeutically effective amount.

- 25 According to another preferred embodiment the blocking compound is a receptor blocking compound.

According to another preferred embodiment the blocking compound is a monoclonal antibody, fragments thereof, peptides or synthetic constructs.

- 30 According to another preferred embodiment a compound having the ability of inhibiting the activation or activity of enzymes generating immunomodulatory fragments is administered in a therapeutically effective amount.

- 35 According to another preferred embodiment the inhibiting compound is a monoclonal antibody, an anti-Integrin antibody, peptides and / or synthetic constructs.

According to another preferred embodiment the modulating substance is an enzyme inhibitor.

According to another preferred embodiment the inhibiting compound is a matrix metalloproteinase inhibitor.

- 5 According to another preferred embodiment any compound blocking the factor inducing IL-6 production is administered in a therapeutically effective amount.

According to another preferred embodiment any compound blocking the factor inducing IL-1 β production is administered in a therapeutically effective amount.

- 10 According to another preferred embodiment any compound blocking the factor inducing IL-10 production is administered in a therapeutically effective amount.

- 15 According to another preferred embodiment any compound blocking the factor inducing TNF- α production is administered in a therapeutically effective amount.

According to another preferred embodiment any compound blocking the factor inducing IL-1Ra production is administered in a therapeutically effective amount.

- 20 According to another preferred embodiment monoclonal antibodies directed to enzymes generating immunomodulatory fragments are administered in a therapeutically effective amount.

- 25 According to another preferred embodiment at least one anti-integrin antibody, peptide or construct is administered in a therapeutically effective amount.

Further preferred embodiments are as follows.

- 30 According to another preferred embodiment blocking cross-linking of FcR is carried out using a therapeutically active amount of FcR antibodies or fragments of monoclonal antibodies directed to FcR, preferably the FcR cross-linking is obtained by administering a therapeutically effective amount of at least one immunoglobulin, more preferably the FcR cross-linking is obtained by administering a therapeutically effective amount of IgG or complex bound IgG, and/or the FcR cross-linking is
35 obtained by administering a therapeutically effective amount of IgA or complex bound IgA.

According to a further preferred embodiment a therapeutically effective amount of Fc part of at least one immunoglobulin is administered, preferably a therapeutically effective amount of Fc part of IgG or complex bound IgG is administered, and/or a therapeutically effective amount of Fc part of IgA or complex bound IgA is administered.

According to a further preferred embodiment any cross-linking of FcγR I, FcγR II and/or FcγR III is carried out.

10 According to a further preferred embodiment FcR is down-regulated using an inhibitor of its expression.

According to another, further preferred embodiment blocking of FcγR is carried out by administering a therapeutically effective amount of anti-FcγR I antibodies.

15 According to another preferred embodiment at least one FcR-blocking substance minimising production of interleukin-1 receptor antagonist is administered in an amount necessary to block the activity of interleukin-1.

20 A further aspect of the invention includes a method for analysing the amount and/or certain pattern of dysregulatory mechanism substances, including their mRNA, including any inducing factor, inducing the production of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, whereby the amount of such dysregulatory mechanism substances is determined in a tissue sample, whereby the prognosis of a subject suffering from cancer can be determined and/or the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored.

30 According to a preferred embodiment tissue is whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, including inflammatory cells.

35 According to another preferred embodiment any compound having the ability of inhibiting the activation or activity of enzymes generating fragments of intra-tumoural tissue are determined.

According to another preferred embodiment any fragment or new epitopes generated by the activity of intratumoural enzymes is determined in any tissue from a cancer patient.

- 5 According to another preferred embodiment the activity of any compound having the ability of inhibiting the activation or activity of enzymes generating fragments is monitored by determining these fragments or new epitopes exposed by the enzymatic activity in any tissue from a cancer patient.
- 10 According to another preferred embodiment the inhibiting compound is a matrix metalloproteinase inhibitor.

- 15 According to another preferred embodiment any compound blocking production or biological activity of a factor inducing pathological production of any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production, is determined.

- 20 According to another preferred embodiment the amount of any inducing factor or mRNA thereof inducing the production of immunoregulatory substances, including one or more cytokines including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α and others, found in tissue, is determined by determining the production of immunoregulatory substances, including cytokines, including, including IL-1Ra, IL-6, IL-1 β and/or TNF- α and others produced by PBMC after exposure to these factors.

- 25 According to another preferred embodiment samples are obtained in a way, including tubes and syringes, not binding or inactivating immunoregulatory substances, including inducing factors.

- 30 According to another preferred embodiment the amount of any inducing factor inducing the production of immunoregulatory substances, including one or more cytokines including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is determined directly.

- 35 According to another preferred embodiment the amount / occurrence of any cell bound factor inducing the production of immunoregulatory substances, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is determined.

According to another preferred embodiment the amount of any urine present inducing factor inducing the production of immunoregulatory substances, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is determined by using an urine dip stick containing binding substance/s binding said inducing factor and/or colour developing reagents to said inducing factor.

According to another preferred embodiment the amount of cell bound immune complexes, CBIC, is determined.

10 According to another preferred embodiment peripheral blood mononuclear cells PBMC being positive for any immunoglobulin staining are determined.

According to another preferred embodiment PBMC being positive for IgG staining are determined.

15 According to another preferred embodiment PBMC being positive for IgA staining are determined.

20 According to another preferred embodiment FcR positive to any immunoglobulin staining is determined, such positive for IgG staining and/or IgA staining.

According to another preferred embodiment the production of O₂⁻ is determined.

25 According to another preferred embodiment down-regulation of the ζ -chain of TCR is determined.

According to another, further preferred embodiment fine needle biopsy TIMC (tumour infiltrating mononuclear cell) being positive to immunoglobulins are determined.

30 According to another preferred embodiment fine needle biopsy TIMC being positive to IgG are determined.

According to a further preferred embodiment fine needle biopsy TIMC being positive to IgA are determined.

35 According to another preferred embodiment IL-1Ra is determined.

According to another preferred embodiment down-regulation of CD28 on CD4+ and/or CD8+ lymphocytes is determined.

5 According to another preferred embodiment down-regulation of CD80 and/or CD86 is determined.

According to another preferred embodiment determination of any other modulation of other immunoregulatory substances is made.

10 According to another preferred embodiment the content of IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , is determined by using an assay, to determine the amount of an inducing factor inducing IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, activity.

15 According to another preferred embodiment the assay utilises any tissue and the determinations are made using any immuno-cyto-histochemical method, any immunoassay including, ELISA, Elispot, RIA and others any blotting technique, including Western blotting, Southern blotting and others, any bioassay, any tissue culture technique, RT-PCR, flow cytometry, cytometric bead array, DNA microarray
20 and / or proteomics.

According to another preferred embodiment dys-regulatory mechanism substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in establishment of micrometastases, are identified.

25 According to another preferred embodiment patients suffering from potential risk are candidates for adjuvant treatment.

According to another preferred embodiment the invention encompasses specific
30 staining methods for IgG in PBMC or biopsies, whereby a first method for determining IgG/IC complexes using a staining, is characterized in that peripheral blood mononuclear cells are separated by centrifugation and spun onto microscope slides; the cells are pre-hydrated using Hank's balanced solution and Hepes solution and human serum albumin, are fixed in phosphate-buffered paraformaldehyde
35 supplemented with glucose, are incubated with biotinylated protein G, followed by incubation with alkaline phosphatase-labelled streptavidin, are incubated in alkaline phosphatase substrate in Tris buffer with dimethylformamide, levamisole and Fast-Red TR salt, are counterstained in Mayer's haematoxylin and mounted in Glycergel;

or alternatively, after fixation and a washing in Hank's balance solution containing goat serum, the cells are blocked in goat serum and are incubated with mouse anti-human IgG monoclonal antibody, are incubated with Envision, are then incubated with the alkaline phosphatase substrate, are then counterstained in Mayer's haematoxylin and are mounted in Glycergel;

and a second method for determining IgG/IC complexes using a staining, is characterized in that a tissue sample is fixed using phosphate-buffered paraformaldehyde in the presence of glucose, is treated with Hank's balanced solution and Hepes solution, incubated with primary antibody, mouse IgG1 anti-human CD3, followed by incubation with goat-anti-mouse immunoglobulin, followed by incubation with PAP mouse monoclonal antibody; using 3,3'-Diaminobenzidine as a substrate resulting in a brown colour, whereby the presence of IgG is then identified using biotinylated protein G by incubation; followed by incubation with alkaline phosphatase-labelled streptavidin followed by incubation with alkaline phosphatase substrate, dimethylformamide, levamisole, and Fast-Red salt, the cells are then counterstained in Mayer's haematoxylin and mounted in Glycergel producing a a bright red staining for IgG, whereby double-stained cells appeared as red-brown

A further aspect of the invention includes a kit for quantitative and/or qualitative analysis of amount of and/or certain pattern of dys-regulatory factor and/or factors inducing the production and/or activation of immunoregulatory substances, whereby prognosis of cancer can be determined and the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored, comprising an indicator for the presence of said dys-regulatory factor/s including inducing factor/s.

According to another preferred embodiment the kit comprises an indicator for the presence of any factor inducing immunoregulatory substances, including cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , and others, activity.

According to another preferred embodiment the kit comprises a nutrient for peripheral blood mononuclear cells and a determinant for inducing factor for inducing immunoregulatory substances including inducing factors of IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others.

According to another preferred embodiment it comprises a urine dip stick comprising binding substance/s and/or colour developing reagents.

According to another preferred embodiment the kit comprises determinants for enzymatic degradation products of tumour substances / extra cellular matrix, ECM.

5 According to another preferred embodiment a matrix metalloproteinaseinhibitor is monitored.

10 According to another preferred embodiment the kit comprises a determinant for dys-regulatory substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in the establishment of micrometastases.

According to another preferred embodiment the amount of cell bound immune complexes, CBIC, is determined.

15 A still further aspect of the invention includes use of at least one regulatory mechanism controlling factor of at least one immunoregulatory substance, including inducing factor of the production or biological activity of Immunoregulatory substances including cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, for the production of a pharmaceutical preparation to be used for
20 therapeutic control and for minimisation of pathological production of immunosuppressive immunoregulatory substances, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , and others or to stimulate production of immunosupportive immunoregulatory substances in a patient suffering from a cancer and to enhance the efficacy and/or possibility of therapeutic treatment of cancer or modulation of
25 dys-regulatory factors to enhance performance status.

According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-
30 17, and/or TNF- α , and others, production in a patient suffering from cancer by therapeutically modulating FcR activity.

According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory
35 substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/Fc γ R activity.

According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by cross-linking FcR/Fc γ R activity.

According to another preferred embodiment at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR cross-linking.

According to another preferred embodiment an agent modulating Fc γ R I, Fc γ R II and/or Fc γ R III used to stimulate IL-2 stimulation of clonal expansion of lymphocytes is used in the manufacture of a pharmaceutical preparation.

According to another preferred embodiment FcR antibodies or fragments of FcR antibodies directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking cross-linking of FcR.

According to another preferred embodiment anti-Fc γ R I, Fc γ R II and/or Fc γ R III antibodies is used in the manufacture of a pharmaceutical preparation for blocking of Fc γ R.

According to another preferred embodiment a compound being able to down-regulate the expression of FcR is used in the manufacture of a pharmaceutical preparation for down-regulating FcR.

According to another preferred embodiment at least one FcR-blocking substance minimising production of interleukin-1 receptor antagonist is used in the manufacture of a pharmaceutical preparation for blocking the activity of interleukin-1.

According to another preferred embodiment at least one FcR-modulating soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins is used in the manufacture of a pharmaceutical preparation.

According to another preferred embodiment at least one FcR-modulating enzyme inhibitor is used in the manufacture of a pharmaceutical preparation.

According to another preferred embodiment at least one FcR-inhibiting matrix metalloproteinase inhibitor is used in the manufacture of a pharmaceutical preparation.

5 According to another preferred embodiment any compound blocking production or biological activity of any factor inducing pathological production of one or more cytokines is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokines.

10 According to another preferred embodiment any factor inducing IL-6 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

15 According to another preferred embodiment any factor inducing IL-1 β production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

20 According to another preferred embodiment any factor inducing IL-10 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

25 According to another preferred embodiment any factor inducing IL-17 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

According to another preferred embodiment any factor inducing TNF- α production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

30 According to another preferred embodiment any factor inducing IL-1Ra production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

35 According to another preferred embodiment a compound having the ability of inhibiting the activation and/or activity of enzymes generating immunomodulatory fragments is used in the manufacture of a pharmaceutical preparation for inhibiting the activation or activity of enzymes generating immunomodulatory fragments.

According to another preferred embodiment antibodies directed to enzymes generating immuno-modulatory fragments are used in the manufacture of a pharmaceutical preparation.

- 5 According to another preferred embodiment at least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof is used in the manufacture of a pharmaceutical preparation.

- 10 A further aspect of the invention includes a pharmaceutical composition comprising a regulatory mechanism controlling factor of an inducing factor of the production or biological activity of immunoregulatory substances including one or more cytokines, for the production of a pharmaceutical preparation to be used for therapeutically control and minimise pathological production of immunosuppressive immunoregulatory substances including one or more cytokine, or or to stimulate
15 production of an immunosupportive immunoregulatory substance in a patient suffering from a cancer to enhance the efficacy and/or possibility of therapeutic treatment of cancer, optionally in combination with therapeutically inert additive to enhance performance status.

- 20 According to another preferred embodiment a FcR modulating agent is present in a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokine production in a patient suffering from cancer by therapeutically modulating FcR activity.

- 25 According to another preferred embodiment a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/Fc γ R activity.

- 30 According to another preferred embodiment at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR activity.

- 35 According to another preferred embodiment an agent modulating Fc γ R I, Fc γ R II and/or Fc γ R III is present to stimulate IL-2 stimulation of clonal expansion of lymphocytes.

According to another preferred embodiment anti-FcγR I antibodies is present in a pharmaceutical preparation for blocking of FcγR.

- 5 According to another preferred embodiment a compound being able to down-regulate the expression of FcR is present in the pharmaceutical preparation for down-regulating FcR.

- 10 According to another preferred embodiment at least one FcR-blocking substance minimising production of Interleukin-1 receptor antagonist is present in the pharmaceutical preparation for blocking the activity of interleukin-1.

According to another preferred embodiment at least one FcR-modulating soluble receptor is used.

- 15 According to another preferred embodiment at least one FcR-modulating enzyme inhibitor is used.

- 20 According to another preferred embodiment at least one FcR-inhibiting matrix metalloproteinase inhibitor is used.

- 25 According to another preferred embodiment a compound having the ability of inhibiting the activation of enzymes generating immunomodulatory fragments is present in the pharmaceutical preparation for inhibiting the activation of enzymes generating immunomodulatory fragments.

According to another preferred embodiment any factor inducing IL-6 production is used.

- 30 According to another preferred embodiment any factor inducing IL-1β production is used.

According to another preferred embodiment any factor inducing IL-10 production is used.

- 35 According to another preferred embodiment any factor inducing IL-17 production is used.

According to another preferred embodiment any factor inducing TNF- α production is used.

5 According to another preferred embodiment any factor inducing IL-1Ra production is used in the manufacture of a pharmaceutical preparation for

10 According to another preferred embodiment a compound blocking a factor inducing pathological production of immunoregulatory substances, including one or more cytokine production is present in the pharmaceutical preparation for blocking a factor inducing pathological production of such immunoregulatory substances.

According to another preferred embodiment antibodies directed to enzymes generating immuno-modulatory fragments are present.

15 According to another preferred embodiment at least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof, is used.

IMMUNOREGULATORY MECHANISMS OF RELEVANCE FOR THE PRESENT INVENTION

20 Published data and the experimental results originally presented below are compatible with dys-regulation of the immune system in cancer patients described herein. Flow-chart 1 shows a summary of the immunoregulatory mechanisms described in this invention. Connections between FcR mediated and dysregulatory factor mediated mechanisms are shown with Roman numerals.

25 There are two main categories of receptors through which IC can modulate the immune system, receptors for the Fc-part of Immunoglobulins and complement receptors. IC can activate complement and receptors for various complement factors are expressed on different types of cells of the immune system. However, large ICs
30 are more complement activating than small ones, which are more immunosuppressive. Thus, binding of complement factors activated by ICs is not a major pathway for induction of immunosuppression.

35 It has been demonstrated beyond any doubt that Fc γ R binding (Geissmann et al., 2001; Wolf et al., 1996) and cross-linking of Fc γ R plays a major role in normal immune regulation. (Gessner et al., 1998; Deo et al., 1997; Lin et al., 2001; Ravetch and Bollag, 2001). These receptors can be either stimulatory or inhibitory and their

cross-linking modulates the production of a large number of cytokines by peripheral blood mononuclear cells (PBMC).

5 Immune complexes, ICs, can influence the activity of various types of cells of the immune system. The effect is highly dependent on the type of cell, which is involved and the characteristics of the immune complexes. In particular the size and whether the immune cells are exposed to soluble or solid phase IC seems to be of importance. Immunocomplexes can be either immunostimulatory or inhibitory depending on their sizes and interaction with different FcRs on immune cells. Large ICs have been
10 demonstrated to be stimulatory whereby small complexes in antigen excess have been demonstrated to be inhibitory to mitogen induced proliferation (e.g. Gupta and Morton, 1981). It has been demonstrated that there is a correlation between the tumour burden and the immunosuppressive activity of immune complexes.

15 Serum blocking factors (SBRs) play a major role in immunosuppression in cancer. They have been shown to inhibit both cytotoxic and proliferative activity of lymphocytes from cancer patients (Baldwin, 1976; Bansal et al., 1976; Hellström and Hellström, 1974). SBRs were demonstrated to be immunocomplexes (ICs), as their inhibitory activity was lost after dissociation at low pH, but reappeared after
20 reconstitution at neutral pH (Sjögren et al., 1971). Tumour associated antigens can frequently be bound in IC (Kirkwood and Vlock, 1984; Vlock and Kirkwood, 1985). Removal of ICs from cancer patient sera, using protein A, also reduced the inhibitory effect of these sera.

25 Data on the prognostic significance of circulating immunocomplexes (CICs) in cancer are somewhat conflicting. In some reports a good correlation to the tumour stage and prognosis has been demonstrated, whereby in others no such correlation was discovered. Based on the results herein this is hardly surprising. The methods used to determine CIC were quite unspecific and were developed to measure only
30 circulating IC. ICs are bound to a large number of cell receptors and the modulatory function of the ICs is mediated via these receptors. It is therefore highly reasonable that ICs are bound to these receptors and that there will be no circulating IC until the receptors are saturated. Thus, cell bound IC will have a profound influence on the function of receptor bearing cells even in the absence of CICs.

35 Th1 helper cells are considered to support the development of cytotoxic activity against the tumour. In malignant tumours, however, a predominance of Th2 over Th1 helper cells has been demonstrated repeatedly. Cross-linking of FcγRs is of

importance also for this diversion of the immune system, as cross-linking induces production of PEG2 (e.g. Berger et al. 1996), which favours a Th2 situation with production of IL-4, IL-10, etc. IL-4 then inhibits the immune reactivity to the tumour partly by down-regulating monokine production in general, but also by stimulating the production of IL-1Ra. Further, IL-4 stimulates the expression of the inhibitory FcγR II, CD32b, and inhibits expression of the stimulatory receptor CD32a (Pricop et al., 2001). Thus blockade of the FcγR mediated triggering of the Th2 predominance in malignant tumours would certainly improve the immune reactivity to the tumour.

- 10 Cross-linking of FcγR by IC can result in activation or inhibition. The latter can be mediated in several ways:
- expression of B7 on monocytes, necessary for co-stimulation in activation of T-cells, is down-regulated;
 - increased production of pro-inflammatory monokines, IL-1β, IL-6, TNF-α by monocytes;
 - production by monocytes of various substances inhibiting the immune reactivity, e.g., PGE₂, TGF-β, sTNF-αR, and IL-1Ra;
 - oxidative burst of O₂⁻ radicals, resulting in down-regulation of the ζ-chain of the T-cell receptor;
 - down-regulation of IL-12;
 - production of interleukin-1 receptor antagonist (IL-1Ra), which blocks the activity of interleukin-1, necessary for immunostimulation, and expression of endothelial adhesion molecules, necessary for recruitment of inflammatory/immune effector cells to the tumours;
 - modulation of endothelial cell function.

Despite that these facts have been known for a very long period of time, it has so far not been suggested that modulation of FcRs/FcγRs is a very attractive therapeutic principle for treatment of the immune system in cancer patients in order that FcR/FcγR mediated immunosuppression is relieved, and the therapeutic efficacy can be significantly improved.

In the present invention, interleukin-2 (IL-2) stimulated proliferation of PBMC and IL-1Ra production and was chosen as relevant markers for FcγR mediated immunostimulation / suppression.

It is shown below, that solid phase IgG (mimicking large ICs) together with IL-2 results in a significantly increased proliferative response to PBMCs from healthy

individuals, as well as cancer patients compared to cultures where solid phase binding was blocked by pre-incubation with human serum albumin (HSA). This effect is most clearly shown when the culture plates were pre-coated with HSA/IgG allowing a high degree of cross-linking of FcγR. The proliferative response to IL-2 could be normalised in cancer patients (compared to controls) using this technique. A stimulatory effect of solid phase IgG was also seen when IgG from serum in the culture medium is allowed to bind to the surface of culture wells. This effect is very clear in cultures of PBMCs from healthy individuals but in about 50% of the cancer patients this stimulation is lost. This stimulatory effect in healthy individuals can be inhibited by adding serum from cancer patients to the culture medium. The mechanism for increased proliferative response to IL-2 in the presence of FcγR cross-linking is reasonably due to an increased production of supportive cytokines.

In this model blockade of FcγR I (CD64), II (CD32), and III (CD16) with F(ab')₂ fragments of monoclonal antibodies directed to these receptors showed that the enhanced proliferative response was inhibited mainly by anti- FcγR I antibodies. These F(ab')₂ fragments thus block the receptors in a way similar to that of small immunocomplexes, ICs.

An immunoregulatory role of CD64 has been demonstrated by (Sutterwala et al., 1998; Szabo et al., 1990 and 1991). The mechanism for the inhibitory effect of anti-CD64 F(ab')₂ fragment as described below in cultures on solid phase IgG is presumably due to a difference in affinity of the F(ab')₂ fragment and the Fc-part of IgG. A higher affinity of the antibody to the receptor will allow blockade of the receptor despite the competition with solid phase IgG. However, if the immunosuppression of PBMC from cancer patients (low proliferative response to IL-2) is due to FcγR blockade by IC, this can actually be overcome by culturing patient PBMC together with IL-2 on solid phase IgG, that is cross-linking of a few FcγR, will be substituted for by a larger number of FcγRs resulting in stimulation.

Based on these considerations one inhibitory mechanism, blockade of FcγR I, can be overcome by providing more extensive cross-linking similar to what is achieved in cultures with solid phase IgG.

The immunomodulatory role of cross-linking of FcγR by solid phase IgG has furthermore been shown by analysing cytokine production in short term cultures of PBMCs with solid phase bound IgG, which in healthy individuals inhibited the production of IL-6. Similarly, in PBMC cultures from both cancer patients and healthy

individuals (less frequently) the production of IL-6, IL-1 β as well as TNF- α were frequently markedly increased when binding of serum IgG was blocked by pre-incubation of the culture wells with HSA. In accordance with these results the production of IL-1Ra, which is induced by IC or solid phase IgG, was reduced in cultures where solid phase binding of IgG was blocked by pre-incubation with HSA.

Interleukin-1 (IL-1) plays a fundamental role for the initiation of an immune response. However, in order to avoid an over-reactivity of the immune system, there are several ways, in which the immunostimulatory activity of IL-1 can be kept under control, e.g., soluble IL-1 receptors, and IL-1 receptor antagonist (IL-1Ra), a very potent inhibitor of IL-1 mediated activity (Arend et al., 1998; Dinarello, 1997). The inhibitory role of IL-1Ra has been clearly demonstrated in studies on autoimmune diseases and rejection after allogeneic organ transplantation.

The most potent inducer of IL-1Ra is IC. As demonstrated below the production of IL-1Ra is significantly increased by PBMCs isolated from cancer patients. Thus, cell bound immuno-complexes (CBICs), have been demonstrated to be involved in the dys-regulation of the immune system in cancer patients.

IL-1Ra obviously plays a central role in down-regulation of immune reactivity. As demonstrated here it is frequently expressed in large areas of malignant tumours. This finding is highly compatible with the occurrence of tissue bound IgG in the tumours as IC or solid phase IgG are the most potent inducers of this cytokine.

Thus two inhibitory mechanisms based on modulation of Fc γ R will be shown below, viz. blockade of Fc γ R, which inhibits IL-2 stimulation of clonal expansion of lymphocytes, and induction of the inhibitory cytokine IL-1Ra. In addition, a more extensive cross-linking of Fc γ R results in normalisation of the suppressed IL-2 induced proliferation in cancer patients.

As pointed out below a large number of therapeutic strategies can be used to avoid this type of down-regulation (Bowles et al., 1997; Fridman et al., 1993). It is demonstrated herein that blocking Fc γ R II (CD32) by a monoclonal F(ab)-fragment significantly reduces the production of IL-1Ra. An alternative therapeutic option is to inhibit the intra-tumoural protease activity, which is known to enhance the efficacy of Fc γ R II interaction (Isashi et al., 1998; van der Winkel et al., 1989).

Thus, the inhibitory effect due to binding of IC to FcγR can be treated using various techniques, e.g. by blocking the inhibitory receptors (see below), by down-modulating the sensitivity of receptors by protease inhibitors or by overcoming the inhibitory effects using more competitive binders / more extensive cross-linking of the receptors. These strategies will be the base for efficient, new therapeutic strategies to overcome immunosuppression in cancer patients.

An increased serum concentration of IL-6 is often found in cancer patients, especially in patients with advanced disease (Barton , 2001; Blay et al., 1992; Blay et al., 1997; Gadducci et al., 2001; Walther et al., 1998). The source of serum IL-6 is still somewhat unclear and it is generally assumed to be derived from the tumour. It is shown herein that this cytokine is produced in large amounts, in short term cultures, by PBMCs from cancer patients and to a much lesser extent, or not at all, by unstimulated PBMCs from healthy individuals. A high serum concentration of IL-6 is generally related to a paraneoplastic syndrome, poor response to immunotherapy and some types of chemotherapy, as well as a poor prognosis.

It is shown that large amounts of IL-6 is produced by PBMCs from about 50% of the cancer patients, as shown in malignant melanoma, renal cell carcinoma, and colorectal cancer. An increased production of IL-6 is also found in patients with only a minimal tumour burden, as about 50% of the patients with radically resected stage III melanoma have a significantly increased production of IL-6.

IL-6 is a pleiotropic cytokine, which acts as an autocrine growth factor in for example renal cell carcinoma and multiple myeloma. It promotes the inflammatory response, induces acute phase reactants as well as IL-1Ra and is involved in the detrimental chronic inflammatory reaction in patients with malignant tumours. It is thus a good marker for dysregulation of the immune system in cancer patients and the paraneoplastic syndrome.

Production of IL-6 can be induced in various ways, e.g., by IL-1β, and TNF-α, and under certain circumstances also by cross-linking of FcR/FcγR. The degree of cross-linking is of importance for the regulatory effect on the production of IL-6. As shown below, the degree of cross-linking achieved by solid phase binding of serum IgG (from a culture medium) inhibits production of IL-6, as pre-coating the culture wells with HSA (thereby blocking the binding of IgG) results in a significantly higher production of IL-6 in about 30% of cancer patients with various diagnoses. Similarly,

IL-6 production was significantly inhibited in cultures of PBMCs from healthy individuals when the culture wells were coated with IgG instead of HSA alone.

5 The mechanism by which isolated PBMCs continue to produce IL-6 in vitro has so far been unresolved. It is shown herein that serum from cancer patients added to PBMCs from healthy individuals, who by themselves do not produce IL-6, induce the production of large amounts of IL-6. As FcγR cross-linking modulates the production of IL-6, sera known to induce this cytokine, were adsorbed by a surplus of protein-G Sepharose to remove all IgG. These adsorbed sera still induced the production of IL-6 even to a greater extent than before adsorption. These results are compatible with that described herein, that is, a reduced interaction of IgG with PBMCs increase IL-6 production. This IL-6 inducing factor has been further characterised by fractionated ultrafiltration, which demonstrates a factor having a molecular weight of less than 50 kD. This factor has also been identified in the urine from cancer patients. The source of this factor was studied and various tumours were minced and extracted with physiological buffers. An IL-6 inducing factor, IL-6IF, is identified in about 60% of the analysed tumours. Similarly, an IL-6 inducing activity has been found in culture conditioned media from squamous cell carcinoma cell lines from the oral cavity.

15
20 Thus this factor, IL-6IF, which has been found in serum and urine, seems to be produced intratumorally. It is neither IL-1β, TNF-α or interleukin-17, as these cytokines could not be found in fractions inducing IL-6.

The identification of IL-6IF in the urine opens interesting diagnostic possibilities.
25 Based on the urine concentration of IL-6IF a simple diagnostic test can be developed which will give essential information about prognosis and the likelihood of therapeutic success, in particular for treatment where IL-6 is related to a poor response rate. This test will of course also be extremely valuable when it comes to treatment strategies dealing with the elimination of IL-6IF / treatment of the chronic inflammatory reaction in cancer patients.
30

Similar to the situation with IL-6 we have also found inducing activity for TNF-α IL-1β and IL-10 in serum and ultra-filtered urine. The number of inducing factors is for the moment unknown but TNF-α inducing activity was found in samples not inducing IL-6. Thus, reasonably several inducing factors are involved in dysregulation of the immune system in cancer.
35

The immunosuppressor factor in trauma patients (Easter et al., 1988; Hoyt et al., 1988) was also found to inhibit migration of inflammatory cells. This mechanism might be of importance in immunosuppression in cancer as in untreated patients, inflammatory cells recruited to the tumour generally are found in the stromal areas surrounding the tumour nodules presumably because of inhibition of their migration close to the tumour cells. As fibronectin is of importance for migration it can be envisioned that if the cell receptors normally binding to fibronectin or other ECM-substances in the migration process are blocked by fragments of these substances the cells will no longer be able to migrate. In this context the phenomenon of leukocyte adherence inhibition is of interest as PBMCs from cancer patients under certain conditions demonstrate a highly reduced ability to adhere to plastic or glass surfaces.

IL-6 has by others been shown to be an inducer of IL-1Ra. However, in the present work based on the available malignant melanoma and renal cell carcinoma materials no correlation between IL-6 and IL-1Ra has been found rather the contrary. FcγR cross-linking inhibits production of IL-6 as shown herein and stimulates IL-1Ra production.

The role of IL-6IF containing sera in the immunoregulation in cancer is demonstrated by its effect on the proliferative response to IL-2. The type of solid phase IgG binding is obviously of importance for the effect of IL-2. Coating the wells with purified IgG mixed with HSA gives a more powerful stimulatory signal than binding of serum IgG from the culture medium (uncoated cultures). There is thus a marked difference in the proliferative rate in uncoated cultures and HSA coated cultures with a higher proliferative activity in the presence of solid phase IgG. This difference can be inhibited by sera containing IL-6IF, either by interfering with stimulatory mechanisms or by modulating monocytes to increased production of inhibitors, such as PGE₂ or IL-1Ra. The inhibitory effect has not been shown in IgG coated cultures, probably because the more forceful effect on the proliferative response to IL-2 under the conditions used.

The importance of serum factors / soluble factors in dysregulation of the immune system in cancer is furthermore shown by the concomitant immunity phenomenon, which means that immune mediated anti-tumour reactivity can be suppressed in the primary tumour allowing local progression of this tumour while there is still a systemic protection against distant metastases (North, 1985). When, however, the

tumour burden is increasing the systemic protection will break down. According to the concept described in this document there will at a certain tumour burden and / or a certain intra-tumoural enzymatic activity be a sufficient systemic concentration of suppressor substances to suppress the immune mediated systemic protection
5 resulting in the establishment of micro-metastases. Thus, by analysing these dysregulatory substances in serum or urine from cancer patients, the patients at high risk of systemic micro-metastases can be identified and these patients are those who should be offered adjuvant treatment.

10 Matrixmetalloproteases (MMPs), frequently found in tumour tissue, can be induced by inflammatory cytokines and are of importance for degradation of extra cellular matrix proteins (ECMs). This activity is considered to be a pre-requisite for metastatic spread, and neo-angiogenesis. Occurrence of MMPs has, in several studies been shown to correlate to a poor prognosis. Obviously, the proteolytic activity of MMPs
15 will result in various types of degradation products, some of which are known to modulate angiogenesis and the activity of chemokines. The low molecular weight fraction, IL-6IF, described herein can be a proteolytic fragment. The presence of the factor in tumour extracts and in culture conditioned media from squamous cell carcinoma cell lines from the oral cavity suggests this origin. It has also been shown
20 in a large number of studies by others that culture conditioned media contain immunomodulatory / immunosuppressive factors (e.g. Ménétrier-Caux et al., 1999; Heimdal et al., 2000; Heimdal et al., 2001). A similar factor with immunosuppressor activity, supposed to be derived from proteolytic degradation of serum fibronectin, has been described in trauma patients (Easter et al., 1988; Hoyt et al., 1988).
25 Factors derived from enzymatic degradation of ECM can most likely be both stimulatory and inhibitory as various cytokine patterns have been induced by various fibronectin fragments (Beezhold and Personius, 1992 ; López-Moratilla et al., 1995; Takizawa et al., 1995) and also it was recently demonstrated that the expression of various MMPs in malignant melanoma was related to therapeutic response and
30 prognosis (Nikkola et al., 2001).

The generally found immunosuppressive effect of malignant tumours can thus very well be due to the increased enzymatic / proteolytic activity of the tumours resulting in various immunomodulatory fragments / fragments of ECM or other tumour
35 substances. In addition to this, the proteolytic activity can also explain the frequent occurrence of a large number of soluble factors of importance for immune reactivity in cancer patients (Salih et al., 2001; Sheu et al., 2001), e.g. sIL-2 receptor, sTNF- α receptors, sCD8, sCD4, sICAM-1, sMHC I, sFcR etc. Intra-tumoural enzymatic activity

also seems to be of importance for activation of pro-TGF- β to active TGF- β (Huber et al., 1992). Based on these considerations intra-tumoural proteolytic activity seems to be a fundamental mechanism by which the malignant tumour manage to divert the tumour bearers defence to the disease.

5

The occurrence of proteolytic fragments of ECM in serum and urine from cancer patients (Katayama et al., 1993) also opens the possibility to identify various types of fragments and analyse their prognostic significance. Furthermore, the therapeutic efficacy of matrixmetalloprotease inhibitors (MMPis) resulting in a reduction /

10 Inhibition of the production of fragments of certain importance can be determined by analysing the amount of these fragments in serum or urine. Determination of these fragments will thus be proper surrogate endpoints for MMPI therapy and have the potential to significantly increase the therapeutic activity of these drugs by allowing monitoring whereby efficacious dose schedules can be developed.

15

Dysregulation of the immune system by enzymatic / proteolytic fragments from various tumour substances (derived from tumour tissue or plasma proteins) has so far not been described. A large number of inhibitory as well as stimulatory fragments can be produced as a result of the intra-tumoural enzymatic activity. This provides
20 for a new understanding of immunosuppression in cancer patients and new therapeutic possibilities based on proper diagnostic tests.

25

All together the data of this invention demonstrate mechanisms whereby dysregulatory factors give rise to a pathological production of proteolytic enzymes and inflammatory cytokines, which also induce the production of proteolytic enzymes by tumour cells, the activity of these enzymes results in an enhanced release of dysregulatory factors, which then further enhance the production of inflammatory cytokines and proteolytic enzymes, thus creating an autocrine loop. The end result of this loop will then be proteolytic enzymes, which will promote angiogenesis and the
30 metastasising potential and divert the immune reactivity to the tumour.

35

The dysregulatory inducing factors were further characterised by using 2D-gel electrophoresis and identified after fragmentation using massspectrometry and N-terminal sequence analysis (proteomics technique). The low molecular weight fraction (<30kD) from urine was analysed by comparing samples from normal healthy controls with samples from patients; by comparing urine samples with and without IL-6 inducing activity; by comparing samples adsorbed and not adsorbed with a surplus of normal PBMCs (responding to IL-6IF). Several proteins / fragments

of potential immunoregulatory activity were thereby identified as described below, e.g. fragments of β 2-microglobulin, serum albumin and immunoglobulin.

As these fragments were identified based on their adsorption to PBMCs,

5 demonstrating a high degree of binding, the occurrence of receptors for these protein fragments / peptides on normal PBMCs sensitive to IL-6IF can be postulated. As albumin and β 2-microglobulin do not normally bind to these cells, it can be further postulated that fragmentation of these proteins results in conformational changes exposing new structures with a specific binding to receptors on PBMCs. As
10 demonstrated herein this results in modulation of the immune system. Thus, the basis for a quite new mechanism of immunomodulation in diseases characterised by a high proteolytic activity, e.g. inflammation and cancer, has been discovered.

Based on identification of IgG and albumin fragments when 2-D gels were compared
15 as described above, these proteins were incubated with MMPs under well-defined conditions. IL-6 inducing activity was found in the supernatants after incubation with MMPs in two different fragmentation buffers. Inducing activity was analysed in cultures with normal PBMCs. In particular incubation of albumin with MMP-1, -2, -3, -13 and incubation of IgG with MMP-2, -3, -7, -13 released IL-6 inducing / modulating
20 activity. Degradation of IgG by MMPs has previously been described (Gearing et al., 2002) and it was suggested that IgG fragments possibly could have a modulatory activity on antibody dependent cellular cytotoxicity (ADCC), but the possibility that these fragments have an immunoregulatory activity in cancer has to our knowledge never been suggested.

25 In an other experiment, fragments of an extra cellular matrix substance, collagen, was found to have a strong inhibitory effect on IL-2 induced proliferation.

It has been described herein described that IL-6IF can be extracted from malignant
30 tumours, e.g. malignant melanoma, renal cell carcinoma, colorectal cancer. These results were confirmed in a new series of experiments, where homogenised tumours were washed three times in PBS or RPMI in order to collect cytokine inducing factors already present in the tumours, so called "preformed inducing factors" (PIF).

35 The tumour sections / homogenates (after being thoroughly washed) were incubated for 24 hours at 37°C together with MMP-2. IL-6 inducing activity could then be demonstrated in of supernatants from several tumours.

Potentially a large number of proteolytic enzymes can be involved in degradation of various tumour substances, therefore adding possible substrates to homogenised, washed tumour tissue might enhance the production of immunoregulatory factors/fragments. In order to further explore the nature of immunomodulating substances/fragments in tumours and based on the observation, mentioned above, that fragments of albumin, IgG and β 2-microglobulin efficiently binds to normal PBMCs, we added albumin or IgG to thoroughly washed tumour sections/homogenates and incubated for 24 h at 37°C. It was then found that addition of IgG and in particular albumin markedly increased the production of IL-6IF as determined in PBMC cultures. Control experiments showed that the enhanced IL-6 inducing activity was not due to any protective activity of the added proteins. Thus it is herein demonstrated that immunomodulating IgG and albumin fragments are produced in the intra-tumoural milieu

Based on our previous results it might seem amazing that incubation of PBMCs with IgG fragments results in an increased production of IL-6 as pre-coating of culture plates with IgG from serum or an albumin/IgG mixture inhibited IL-6 production. A reasonable explanation to this effect is that the IgG fragments produced by proteolytic degradation manage to block the inhibitory effect of natural IgG. This opens up further interesting possibilities to modulate FcR mediated immune regulation.

Further analyses of PIF-fractions by isoelectric focusing and preparative electrophoresis have identified two fractions with IL-6 inducing activity, with different pI. Preparative electrophoresis also identified two fractions, of different molecular weight, with activity.

CONCLUSIONS

Factors dys-regulating the immune system in cancer patients were found in tumour tissue, conditioned culture media from cancer cell lines, serum and urine.

Control of the intra-tumoural enzymatic / proteolytic activity is thus a fundamental mechanism to control the malignant tumour management of diverting the immune mediated defence system of the tumour bearer against the disease.

Thus both Fc γ R cross-linking and dysregulatory inducing factors (ECM enzymatic / proteolytic fragments) play a fundamental role in immunosuppression in cancer

patients. Therapeutic control of these dys-regulatory mechanisms will thus improve quality of life, therapeutic response and increased over-all survival.

As IL-6 is only one product of the dys-regulated inflammatory reaction mentioned herein and often is correlated to production of other cytokines such as IL-1 and TNF- α ; the strategy is to block the fundamental dys-regulatory mechanisms in order to down-regulate the detrimental chronic inflammatory reaction.

The present invention is thus not based on suppression of the activity of e.g., IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , and others, but to prevent or minimise their production.

DEFINITIONS

In the present description the term "tissue" shall be understood to encompass whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, as such including inflammatory cells.

In the present description the term cancer means: Any new and abnormal growth, specifically a new growth of tissue in which the growth is uncontrolled and progressive.

THERAPEUTIC POSSIBILITIES TO IMPROVE IMMUNE REACTIVITY IN CANCER BY MODULATION OF FcRs

By modulation of FcR either relief of immunosuppression or an enhanced immune activation can be achieved as demonstrated in the present document. Several substances can be used to block FcRs e.g. antibodies or fragments thereof (e.g. F(ab')₂ or Fab-fragments, of Mab directed to Fc γ R) , peptides (e.g. from the Fc-part of IgG) or synthetic constructs. The interaction between receptor binding ligands and the receptor can also be achieved by blocking the binding site of the ligand by using, soluble FcRs (recombinant) or peptides or synthetic constructs with a specific high binding affinity. Finally, the signal transduction resulting from ligand binding to FcRs can be inhibited by signal transduction inhibitors. In addition to these modes of interfering with FcRs, their reactivity is influenced by proteolytic activity and can thus be modulated by protease inhibitors. In this context MMPis can be of special interest.

Alternatively the ligands of FcRs, immunoglobulins or complexed immunoglobulins, can be eliminated and their immunosuppressive activity can thereby be avoided. Recombinant FcRs or synthetic constructs with this reactivity of proper affinity and size can be administered in order that CIC (especially small CICs) are bound and eliminated. To further enhance the elimination of CICs binders of these substances can be linked to small microspheres (less than 3-5 mm in diameter, possibly degradable) which are rapidly taken up by the reticulendothelial system / monocyte macrophage phagocyte system.

- 10 Another therapeutic possibility is to reduce the number of FcRs which can have a negative effect of the Immune reactivity to the malignant tumour, e.g. by increasing their shedding or by down-regulation of their expression.

- 15 An alternative to block FcRs, which result in down-regulation of the immune reactivity, can, as has been demonstrated in this document, be to cross-link FcRs in order to overcome immunosuppression. Several possibilities can be used for this purpose, e.g. complexed immunoglobulines / monoclonal antibodies or fragments (Fc) thereof binding to the receptors or synthetic FcR-binding constructs, cross-linking FcR to a degree (number of FcRs of one or several types) achieving optimal immune activation.

THERAPEUTIC POSSIBILITIES TO IMPROVE IMMUNE REACTIVITY IN CANCER BY CONTROLLING DYS-REGULATORY INDUCING FACTORS.

- 25 Inhibition of the fragment's biological activity (e.g. by monoclonal antibodies or fragments or synthetic constructs binding to and inhibiting the biologic activity of the fragments, synthetic constructs binding to the receptors mediating the biologic effect of the fragments, blockade of the receptors on immune cells, protein fragments / peptides interfering with the receptor interaction of the fragments and thereby inhibiting the biological activity of the fragments.); Elimination of the fragments from the body (e.g. by monoclonal antibodies (or fragments) or other "binders" binding to and eliminating the fragments); Signal transduction inhibitors, blocking the effect of receptor binding; Blocking the activity of the "dysregulated signal substances / cytokines.

- 35 If these factors are generated by enzymatic activity resulting in release of immunomodulatory fragments, the following therapeutic possibilities can be envisioned: Inhibition of the production and activation of the relevant enzymes (e.g.

by anti-integrin antibodies or suitable peptides); Inhibition of these enzyme activities (e.g. by low molecular weight inhibitors, monoclonal antibodies or peptides);

MATERIALS AND METHODS

- 5 Cytospin preparations for immunocytological demonstration of IgG
Peripheral blood mononuclear cells (PBMC) were separated as described below and immediately spun down on pre-cleaned microscope slides in a Shandon Cytospin (Shandon Scientific Ltd, UK) at 1000 RPM for 7 min using 100 µl of the PBMC suspension at 5×10^5 /ml. The slides were left to dry at room temperature over
- 10 night, were then wrapped in parafilm and stored -70°C until further processed. The cells were pre-hydrated in BSS-HSA (Hank's balanced salt solution (BSS, Gibco BRL, UK) supplemented with 0.01M. Hepes solution and 1% human serum albumin (HSA, Pharmacia&Upjohn, SE), for 15 minutes, fixed in phosphate-buffered 4% paraformaldehyde (PFA, Riedel-de Haen Ag, Germany) supplemented with 5.4 g./l. of
- 15 glucose for 5 minutes and then washed three times in BSS-HSA, incubated with biotinylated protein G (Sigma Chemical Co, US) at 50µg/ml for 30 minutes, washed in BSS-HSA followed by incubation with alkaline phosphatase-labelled streptavidin (Dakopatts AB, SE) at a 1/100 dilution in BSS-HSA for 30 minutes. After washes in Tris buffered saline (TBS) and incubation for 20 minutes in alkaline phosphatase
- 20 substrate consisting of Naphtol AS-MX Phosphate (Sigma) in 0.1 M Tris buffer with Dimethylformamide, 1 M Levamisole (Sigma) and Fast-Red TR salt (Sigma), the sections were again washed in TBS. They were then counterstained in Mayer's haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB). All incubations were performed in a moist chamber and all antibody and protein-G solutions were
- 25 prepared in BSS-HSA. Alternatively, after fixation and washing in BBS containing 2% goat serum, the cells were blocked in 10% goat serum for 20 minutes and incubated with mouse anti-human IgG monoclonal antibody (Nordic Immunology) at 1 or 10µg/ml, washed in BSS containing 2% goat serum, incubated with Envision (Dakopatts AB, SE) for 30 minutes, washed in TBS and incubated with the alkaline
- 30 phosphatase substrate for 20 minutes after which the sections were again washed in TBS. They were then counterstained in Mayer's haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB, SE). All incubations were performed in a moist chamber and all antibody solutions contained 2% normal goat serum.
- 35 Preparation of tumour biopsies and immunological staining of tissue sections for IgG
Biopsies from the resected metastases were immediately snap frozen and stored at -70°C until further processed. Frozen tissue sections, 6-7 µm thick, were fixed with 4% PFA for 5 minutes and then washed three times in BSS-HSA. For double-staining,

sections were incubated with primary antibody, mouse IgG1 anti-human CD3 (Dakopatts AB), at 1µg/ml for 30 minutes, washed in BSS-HSA followed by incubation with goat-anti-mouse immunoglobulin (Dakopatts AB, SE) at a 1/25 dilution in BSS-HSA. Monoclonal mouse IgG1 against an irrelevant antigen (Dakopatts AB, SE) was used as a negative control. The sections were then incubated with PAP mouse monoclonal antibody (Dakopatts AB, SE) at a 1/25 dilution in BSS-HSA for 30 minutes. 3,3'-Diaminobenzidine (DAB, Sigma) was used as a substrate, which resulted in a brown colour. The presence of IgG was then identified using 1 or 10 µg/ml biotinylated protein G (Sigma) which was incubated for 30 minutes, washed in BSS-HSA, followed by incubation with alkaline phosphatase-labelled streptavidin (Dakopatts AB, SE) at a 1/100 dilution in BSS-HSA for 30 minutes. After washes in TBS and incubation with alkaline phosphatase substrate for 20 minutes, the sections were again washed in TBS. They were then counterstained in Mayer's haematoxylin for 1 minute and mounted in Glycergel (Dakopatts AB, SE). All incubations were performed in a moist chamber and all antibody and protein-G solutions were prepared in BSS-HSA. The alkaline phosphatase staining resulted in a bright red staining for IgG. Double-stained cells appeared as red-brown.

Preparation of tumour biopsies and immunological staining of tissue sections for Interleukin-1 receptor antagonist (IL-1Ra).

Paraffin sections, 6-7 µm thick, were de-paraffinised by cooking in a pressure cooker in BSS with 0.01 M Hepes solution and 1% saponin (Sigma) (BSS-saponin) for 6 minutes. The sections were first blocked with 10% normal human AB-serum before staining and were then incubated with biotinylated goat IgG antibodies directed either to interleukin-1α or interleukin-1 receptor antagonist (both from R&D Systems, UK) at 10 µg/ml over night, washed in BSS-saponin, incubated with alkaline phosphatase-labelled streptavidin (DAKO, SE) at a 1/100 dilution in BSS-saponin containing 2% human AB-serum for 30 minutes. After washes in TBS and incubation with the alkaline phosphatase substrate for 20 minutes, the sections were again washed in TBS and were then counterstained in Mayer's haematoxylin for 1 minute and mounted in Glycergel (Dakopatts, Sweden). All incubations were performed in a moist chamber and all immunoglobulin solutions were prepared in BSS-saponin containing 2% human AB-serum. Staining for interleukin-1α was used as a negative control in this context.

Preparation of peripheral blood mononuclear cells (PBMC)

Venous blood was drawn from healthy volunteers or from cancer patients in glass vacuum tubes with acid dextrose citrate solution A as an anti-coagulant (Vacutainer,

Becton & Dickinson, NJ). Erythrocytes were removed by sedimentation on 2% dextrane T500 solution (Amersham Pharmacia Biotech AB, SE) in 0.9% NaCl. Mononuclear cells were then isolated by Ficoll-paque Plus (Pharmacia AB, SE) density gradient centrifugation after which the cells were washed twice in RPMI1640 Dutch's modification (RPMI) (Gibco BRL, Scotland) with 2% human serum albumin (HSA) (Pharmacia & Upjohn, SE). Cell viability was assessed by exclusion of 0.05% Trypan Blue and was always above 95%. The cell suspension was stained with Turks solution and the number of lymphocytes and monocytes in the PBMC preparation were counted in a hemocytometer. PBMCs were suspended in RPMI with 2% HSA and the cell concentration were adjusted to 5×10^5 lymphocytes/ml.

PHA stimulated proliferation of PBMC with and without chlorambucil

Venous blood was drawn at the indicated time points from RCC patients undergoing IL-2 (Proleukin, Chiron, NL) therapy. Mononuclear cells were isolated by Ficoll-Isopaque (Pharmacia, SE) density gradient centrifugation. 5×10^4 PBMC in a final volume of 200 μ l were seeded into round-bottomed microtiter plates (Corning Inc. NY, US) in culture medium consisting of RPMI 1640 supplemented with 100 IU/ml Penicillin, 100 μ g/ml Streptomycin (Flow laboratories) and 10 % heat-inactivated, autologous fresh serum. Phytohemagglutinin (PHA, Sigma Chemical Co, MO, US), at a final concentration of 20 μ g/ml, and Chlorambucil (CHL, Sigma), at a final concentration of 1 μ g/ml, were then added. Cells were cultured for 3 days in a humidified 5% CO₂ atmosphere at 37° C. Proliferation was assayed by incorporation of 1.6 \square Ci/well of [³H]thymidine (Amersham Int, UK) during the last 18 hr. Mean values of dpm (disintegrations per minute) of triplicate cultures were used for the calculations.

Measurement of TNF- \square in PHA stimulated cultures

PHA-stimulated cultures with or without chlorambucil (1 \square g/ml) were set up in parallel as described above for mitogen-stimulated cultures. Supernatants were collected after 72 hours and cells were removed by centrifugation for 5 minutes at 4000 RPM. The SNs were frozen immediately and stored at -70°C. The amount of TNF- α in the SNs was evaluated with an ELISA kit from Immunotech S.A., FR, according to the manufacturer's instructions. The lower limit of detection in this assay was 10 pg/ml.

Pre-coating of culture plates with HSA and HSA/IgG

Round-bottomed, 96-well tissue culture plates (Costar, Corning Inc. NY, US) were pre-coated with HSA only or HSA and pooled human IgG for intravenous injection

(Gammagard, Baxter AS, DK). HSA was diluted in RPMI1640 without supplements to a concentration of 10 mg/ml. In some experiments, 1 mg/ml IgG was mixed into a solution of 9 mg/ml HSA in RPMI (HSA/IgG). 200 µl of HSA or HSA/IgG were then added to each well of the plate. The plates were incubated at 4°C for 30 minutes after which the wells were washed twice with 200 µl of RPMI1640. The coated plates were used immediately.

IL-2 induced proliferation of PBMC in uncoated and coated culture plates

100 µl of RPMI1640 supplemented with 200 IU/ml penicillin, 200 µl/ml streptomycin, 4 mM L-glutamine (all from Sigma Chemical Co. MO, US) and 20% heat-inactivated human serum (autologous or from cancer patients) were added to uncoated, HSA or HSA/IgG coated tissue culture microtiter plates. PBMC, isolated from healthy individuals or patients with metastatic renal cell carcinoma, were diluted in RPMI/2%HSA at a concentration of 5×10^5 /ml and 100µl were added to the microtiter wells. Interleukin-2 (IL-2, Proleukin, Chiron, NL), at a final concentration of 120 IU/well, was added to some wells. Cells were cultured for 7 days in a humidified, 5% CO₂-atmosphere at 37°C. Proliferation was assayed by incorporation of 1.6 µCi/well of [3H]-thymidine (Amersham Int., UK) during the last 18 hrs. Mean values of dpm (disintegrations per minute) of triplicates were used for the calculations.

Inhibition of IL-2 induced proliferation of PBMCs by monoclonal antibodies to FcγR.

Cultures for IL-2 induced proliferation were set up with PBMC from healthy individuals as described above with the exception that the PBMC were first pre-incubated with antibodies against human FcγR as follows: PBMC, at a concentration of 5×10^5 /ml in RPMI/2%HSA, were incubated at room temperature for 30 minutes with 25 µg/ml of F(ab')₂ mouse anti-human CD16 (FcγR III), CD 32 (FcγR II), or CD 64 (FcγR I) (all purchased from Ancell Co. MN, US). 100 µl of the respective antibody-containing cell suspension was then added to the microtiter wells.

Generation of cell culture supernatants for monokine determination

100 µl of culture medium consisting of RPMI1640 supplemented with 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (Sigma Chemical, MO, US) and 20% fresh heat-inactivated autologous serum were added to un-coated or -pre-coated microtiter plates followed by 100 µl of PBMC suspension (5×10^4 lymphocytes) in RPMI/2%HSA. In some experiments Lipopolysaccharide (LPS, Sigma Chemical Co, MO, US) was added at a concentration of 0.05 ng/ml. Cells were cultured in a humidified, 5% CO₂ atmosphere at 37°C. Supernatants (SNs) were

harvested after 24 hrs and residual cells were removed by centrifugation in a refrigerated centrifuge (Beckman) at 2600 x g for 5 minutes. SNs were frozen and stored at -70°C until monokine concentrations were measured by ELISA.

5 Monokine ELISAs

Monokines were assessed by ELISA using the DuoSet ELISA development system for human IL-6, TNF- α or IL-1 β (R&D Systems Europe, Ltd. UK) following the manufacturer's recommended procedures. Lower limit of detection was 3.1 pg/ml for IL-6, 15.6 pg/ml for TNF- α and 3.9 pg/ml for IL-1 β . IL-10 was detected with a kit from Diaclone Research, FR. The lower limit of detection was 5 pg/ml. Human IL-1Ra was detected with a quantitative sandwich ELISA using a monoclonal mouse anti-human IL-1Ra as capture antibody and a biotinylated goat anti-human IL-1Ra as developing antibody (both from R&D Systems). Briefly, enhanced binding 96-well microtiter plates (Labsystems AB, SE) were coated overnight at room temperature with 10 μ g/ml of capture antibody diluted in PBS. After washing in PBS with 0.05% Tween 20 (Sigma Chemical, MO, US) plates were blocked with a blocking buffer consisting of 1% bovine serum albumin (BSA, Sigma), 5% sucrose (Sigma) and 0.05% NaN₃ in PBS. PBMC culture SNs or recombinant human IL-1Ra standard (R&D Systems) were diluted in 0.1% BSA and 0.01% Tween 20 in PBS (dilution buffer) and incubated over night at room temperature. After washing, the biotinylated-developing antibody was added at 100 ng/ml in dilution buffer. This was incubated for 1 hr at room temperature. Plates were washed and alkaline phosphatase (ALP)-conjugated Extravidin (Sigma), at a dilution of 1:10000 in Tris buffered saline with 0.1% BSA was added. Following incubation for 1 hr at room temperature, plates were washed and the amount of bound IL-1Ra was measured by hydrolysis of paranitrophenyl phosphate (Sigma). Optical density was read at dual wavelengths, 405 nm and 570 nm, respectively, in a Multiscan EX microplate reader (Labsystems). The lower limit of detection in this assay was 39 pg IL-1Ra/ml

30 Inhibition of IL-1Ra production by PBMC with antibodies against Fc γ R II
PBMCs, isolated from healthy volunteers were pre-incubated at 1×10^6 /ml in RPMI1640 + 2%HSA with 5 or 50 μ g/ml of azide-free, mouse anti-human CD32 Fab (Medarex Inc. NJ, US) for 1 hr at 37°C under gentle agitation. The cells (5×10^5 /well) were immediately seeded onto uncoated or HSA/IgG coated tissue culture microtiter
35 plates in RPMI1640 with 10% heat-inactivated, pooled human AB sera. Supernatants were harvested after 24 hrs, as described under "generations of cell culture supernatants", and the production of IL-1Ra was measured by ELISA.

Inhibition of IL-1Ra production by PBMC with Tosyl

PBMC (2×10^6 /ml) from healthy volunteers were pre-incubated with various concentrations of Na-p-Tosyl-L-lysine chloromethyl ketone (Tosyl, Sigma) diluted in RPMI1640/2%HSA for 30 minutes at 37°C after which the cell suspensions were washed three times in RPMI/2%HSA. 100 µl of culture medium consisting of RPMI1640 supplemented with 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (all from Sigma) and 20% fresh heat-inactivated autologous serum were added to the HSA or HSA/IgG pre-coated microtiter plates followed by 100 µl of the PBMC suspensions (5×10^4 lymphocytes) in RPMI/2%HSA. Cells were cultured in a humidified, 5% CO₂ atmosphere at 37°C. Viability of cultured PBMCs were also assessed after 24 hrs by Trypan blue exclusion and found to be 100%. SNs were harvested after 24 hrs and residual cells removed by centrifugation in a refrigerated centrifuge at 2600 x g for 5 minutes. SNs were frozen and stored at -70°C until IL-1Ra concentration was determined by ELISA.

Preparation of samples for testing of monokine-inducing activity

Below it will be described the handling of various samples that were co-cultured with PBMCs from healthy individuals in order to assess monokine-inducing activity. The samples included human serum and urine (collected from cancer patients and normal healthy individuals), extracts from tumour biopsies and conditioned media from human tumour cell lines. The numbers assigned to patient samples and control PBMCs in the result tables are only valid for that particular table.

Affinity chromatography of human sera with protein G-coupled Sepharose

Heat-inactivated human serum was passed over a HiTrap protein G-Sepharose HP affinity column (Amersham Pharmacia Biotech AB, SE). The non-binding fraction was eluted with RPMI1640, giving a final dilution effect of 1/5 (20%) of the original serum. 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (all from Sigma) were added. The eluate was then sterile filtered with a 0.45 µm Millex syringe filter (Millipore Co. MA, US) and used immediately for culture with control PBMC. 100 µl medium with 20% original serum or with 20% protein G non-binding serum from the same source was added to uncoated or HSA-coated microtiter plates together with 100 µl PBMC suspension (5×10^5 /ml). Cell-free SNs were harvested after overnight incubation and tested for monokine activity by ELISA, as described above.

Ultra filtration

All ultra filtrations were carried out using Amicon Centriplus centrifugal filter devices (Millipore Co. MA, US) sterilised by autoclave. Filters with a 3000, 50000, or 100000

molecular weight cut-off were used. The Centriplus filters were washed with RPMI1640 prior to use. The Centriplus filters were spun on a refrigerated centrifuge with a swing-out rotor at 3000 x g. Retentates were recovered by inverse centrifugation at 2000 x g.

5

Serum samples

Sera, collected from cancer patients or from normal healthy individuals, were heat-inactivated for 30 minutes at 56°C and frozen at -70°C. After thawing, sera were diluted in RPMI1640 to a concentration of 20% and either used unfiltered or ultra-
10 filtered, as described below, in co-culture experiments for monokine-induction with control PBMC. Ultra filtered serum fractions consisted of filtrates from 100000 mw cut-off filters, retentates or filtrates from 50000 mw cut-off filters or retentates from serum fractions that had been sequentially spun on a 50000 mw cut-off filter followed by concentration on a 3000 mw cut-off filter. Retentates were reconstituted
15 in RPMI1640 with 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (Sigma) to their original volume. 100 µl of diluted sera (20%) or ultra filtered serum fractions were added to uncoated or HSA-coated microtiter plates together with 100 µl PBMC suspension (5×10^5 /ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.

20

Urine samples

Approximately 15 ml of urine were collected from cancer patients with renal cell carcinoma or malignant melanoma or from normal healthy individuals. The samples were centrifuged for 10 minutes at 3000 x g followed by filtration over a 0.45 µm
25 Millex-HV syringe filter (Millipore). Next the samples were ultra filtered through a 50000 mw cut-off Centriplus filter and the filtrate concentrated on a 3000 mw cut-off filter. The volume of the retentate, collected from the 3000 mw filter was adjusted to 1 ml with RPMI1640. The sample was then again filtered on a 0.45 µm Millex-HV syringe filter and frozen at -70°C. Immediately before co-culture with normal PBMC,
30 the samples were thawed and buffer exchange was performed to RPMI1640 with 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (Sigma) by gel filtration over a Sephadex-G25 (PD-10) desalting column (Pharmacia, SE).

Extracts from tumour biopsies

35 Human tumour biopsies from patients with renal cell carcinoma, malignant melanoma or colon carcinoma, were embedded in glycergel (Dakopatts AB, SE) and frozen at -70°C. For generation of tumour extracts, approximately 8 to 20, 50 µm cryostat sections were cut and transferred to 4 ml of cold RPMI1640 with 200 IU/ml penicillin,

and 200 µg/ml streptomycin (RPMI/PEST) (Gibco BRL) and kept on ice. The sections were centrifuged and resuspended in 0.5 ml fresh RPMI/PEST after which they were disaggregated in a Medimachine (Dako A/S, DK) using a sterile Medicon 50 µm unit. The disaggregated sample was suspended in 2 ml RPMI/PEST, vortexed and kept on ice for 0.5 to 2 hrs. The sample was centrifuged 10 minutes at 300 x g and the supernatant was harvested. The supernatant was then filter sterilised through a 0.45 µm Millex-HV syringe filter (Millipore). For generation of extracts from fresh tumour biopsies, a newly excised biopsy (about 5 mm³) was disaggregated in a Medimachine (Dako AS), using a sterile Medicon 50 µm unit and resuspended in a total volume of 5 ml TCN buffer (50 mM Tris, 50 mM NaCl, 10 mM CaCl₂ + 200 IU/ml penicillin and 200 µg/ml streptomycin). The cell suspension was incubated on ice for 1 hr. The sample contained 2.7×10^6 cells/ml with a viability of 15%. A cell-free supernatant was harvested after the cells had been pelleted for 10 minutes at 300 x g. The supernatant was then filtered through a 0.45 µm Millex-HV syringe filter (Millipore). Supernatants, extracted from frozen or fresh biopsies were then ultra filtered as described above. Before co-culture with control PBMC, the TNC buffer was exchanged to RPMI1640 with 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (Sigma) by gel filtration over a Sephadex-G25 (PD-10) desalting column (Pharmacia). SNs, 100 µl, were added to uncoated microtiter plates together with 100 µl PBMC suspension (5×10^5 /ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.

Conditioned media from tumour cell lines

Established human, squamous cell carcinoma cell lines, UT-SCC-10 and UT-SCC-20A (a gift from Dr. R. Grenman, University of Turku, Finland) were cultured in 5 ml media consisting of Dulbecco's modified Eagle's medium (DMEM) supplemented with 1 mM L-glutamine, 18 mM Hepes, 0.9% non-essential amino acid solution, 100 IU/ml penicillin, 100 µg/ml streptomycin (all from Gibco) and 10% heat-inactivated human AB-serum (DMEM) in 25 cm³ cell culture flasks (Costar) at 37°C and 5% CO₂. The medium was decanted off and replaced every 2 to 3 days. When the cells had reached confluence they were trypsinated and reseeded in new flasks. The decanted medium was centrifuged at 1000 x g to remove residual cells and debris and then ultra filtered on Centriplus filters with a 50000 mw cut-off. The filtrate was then concentrated on a 3000 mw filter. In some experiments the retentate from the 50000 mw cut-off filter was also saved. Retentates were resuspended in RPMI1640 to 2.5 ml. Before culture with PBMCs the medium was exchanged to RPMI1640 with 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (Sigma) by gel filtration over a Sephadex G-25 (PD-10) desalting column (Pharmacia). In some experiments

parallel culture flasks containing only culture medium and no tumour cell lines were set up as a control. Supernatants from these flasks were treated exactly the same as supernatants from flasks containing cells. Filtrates and retentates were saved at 4°C before co-culture with normal PBMC. SNs, 100 µl, were added to uncoated or HSA-coated microtiter plates together with 100 µl PBMC suspension (5×10^5 /ml). Cell-free SNs were harvested after over-night incubation and tested for monokine activity by ELISA, as described above.

Affinity chromatography with gelatine-coupled Sepharose

Pre-swelled gelatine Sepharose 4B (Pharmacia Biotech AB, SE) was washed three times in PBS or RPMI1640. 0.3-0.5 ml Sepharose gel was incubated together with the 3-50 kD fractions of ultra filtered serum, diluted in 2-2.5 ml RPMI1640 for 30 minutes at room temperature. The gel was mixed gently by inversion approximately every 10 minutes. An equal portion of the ultra filtered serum sample was incubated in parallel without gelatine Sepharose, as a negative control. The gel was allowed to settle and the supernatant collected. Buffer exchange to RPMI1640 with 200 IU/ml penicillin, 200 µg/ml streptomycin, 4 mM L-glutamine (Sigma) was performed by gel filtration over a Sephadex-G25 (PD-10) desalting column (Pharmacia) followed by filtration on a 0.45 µm Millex-HV syringe filter (Millipore). SNs, 100 µl, were added to uncoated microtiter plates together with 100 µl of control PBMC suspension (5×10^5 /ml). Cell free SNs were harvested after over-night incubation and tested for monokine activity by ELISA as described above.

Sample preparation for proteomics

Urine samples (100 – 450 ml) from cancer patients or healthy controls were ultra centrifuged on Jumbosep centrifugal devices (Pall Life Science, MI, US) using a 30 K membrane insert or alternatively, with a Proflux M12 system using a 30 K Pellicon 2 mini filter (Millipore, MA, US) followed by concentration on Jumbosep with a 3K membrane insert. The urine fraction, 3-30 KD, was tested for monokine-inducing activity as previously described herein. Protein concentrations were determined by Bio-Rad protein assay (Bio-Rad Laboratories, CA, US). Samples were desalted over a Sephadex-G25 (PD-10) column (Amersham Biosciences, SE), lyophilised and dissolved in rehydration buffer (8M urea, 4% CHAPS, 10mM DTT, 0.5% v/v IPG buffer and a trace of orange G). Samples were centrifuged to remove undissolved material.

2-DE gel electrophoresis

2-DE was performed in a horizontal 2-DE set-up (Multiphore/IPGphor, Pharmacia Biotech, SE) as described (Lindahl M. et.al 1998) based on isoelectric focusing (IEF) in the first dimension and molecular mass in the second dimension. Briefly, samples (230µg, 350µg, 600µg) were applied to IPG gels, pH 4-7, (Amersham Pharmacia Biotech, SE) and focused overnight for 48000Vh. SDS-PAGE was then carried out with 16% T/1% C polyacrylamide casted slab gels. Molecular weight standards were included in each run. Separated proteins were detected by Coomassie blue staining or SYPRO Ruby staining. The protein patterns in the gels were analyzed as digitised images using a CCD (Charged-Coupled Device) camera (1340 x 1040 pixels) in combination with a computerized imaging 12-bit system, PDQuest Version 6.1.0, in the case of fluorescent stained gels using UV scanning illumination mode (Fluor-S Multi-imager, Bio-Rad). The amount of protein in a spot was assessed as background-corrected optical density, integrated over all pixels in the spot and expressed as integrated optical density (IOD).

Mass spectrometry

Tryptic digests of excised protein spots were performed using MALDI_TOF MS (Voyager-DE PRO, Applied Biosystems, CA, US) as previously described (Ghafouri B. et al. 2002)

Electrotransfer and N-terminal sequence analysis

Selected protein spots were electro transferred to PVDF membranes and subjected to N-terminal sequence analysis by Edman degradation in a Procise cLC or a Procise HT sequencer (PE-Applied Biosystems) at the Protein Analysis Center, Karolinska Institute, Stockholm, Sweden.

Proteomics on PBMC-adsorbed urine fractions from cancer patients

PBMC were prepared from buffy coat peripheral blood from normal controls as described above. Monokine production by the PBMCs in response to urine fractions from cancer patients was verified as described above. Remaining PBMC were frozen at -70°C until use. For adsorption of urine fractions, the PBMCs were thawed and washed carefully in cold phosphate buffered saline (PBS). Approximately 50×10^6 PBMC were added to 2.7 or 2.6 ml, respectively, of ultra centrifuged (3-30 KD) urine fractions pooled from two patients with renal cell carcinoma or from one patient with malignant melanoma. Unabsorbed urine fractions, used as controls, received the equivalent volume of PBS without PBMC. The urine fractions were incubated for 1½ hour at 4°C. The PBMC were then removed by centrifugation. The adsorbed urine fractions were tested for monokine-inducing activity in fresh, normal PBMC as

described above. Remaining urine fractions were stored at -70°C until determination of protein concentration and analysis with 2-D gel electrophoresis, mass spectrometry and N-terminal sequencing as described above.

- 5 Fragmentation of IgG and serum albumin using matrix metalloproteinases (MMPs) MMP -1, -2, -13 (R&D Systems) and MMP-3 and -7 (Chemicon, UK) were activated according to instructions of the manufacturer. 1-50 ng/ml of the indicated MMPs were then incubated with 1 mg/ml of either human serum albumin (HSA, Octapharma, SE) or pooled human IgG for intravenous injection (IvIg, Gammagard, Baxter, DK) as
- 10 substrate in RPMI or in 50 mM Tris-HCl, pH 7.5 (containing 0.15 M NaCl, 10 mM CaCl_2 and 0.05% Brij35). The mixtures were incubated for 5-20 hours at 37°C . Parallel incubations of MMP or the substrates alone, in respective buffer, were set up as controls. The mixtures were buffer exchanged to RPMI as described previously and filtered through a $0.45\text{ }\mu\text{m}$ Millex-HV syringe filter (Millipore, MA, US). Storing of
- 15 mixtures, when needed, was performed at -70°C until analysing by gel-electrophoresis and testing for monokine inducing activity in fresh, normal PBMC as described above.

- IL-2 induced proliferation of PBMC in the presence of collagen / collagen fragments
- 20 Purified collagen from human skin (Sigma) at a concentration of $100\text{ }\mu\text{g/ml}$ was incubated in 100 mM Tris-HCl, pH 7.6, containing 0.15 M NaCl, 10 mM CaCl_2 and 0.05% Brij35 over night at 37°C . The buffer was then exchanged to RPMI1640 by gel filtration through a Sephadex-G25 (PD-10) column (Amersham Biosciences) and filtered through a $0.45\text{ }\mu\text{m}$ Millex-HV syringe filter (Millipore) and frozen at -70°C
- 25 until use. The collagen was tested for effect on IL-2 stimulated proliferation of PBMC from healthy donors in the presence of autologous serum as described. Final concentration of collagen in the proliferation assay was $26\text{ }\mu\text{g/ml}$.

Homogenisation of tumour biopsies

- 30 Frozen, human tumour biopsies, embedded in Tissue-Tek OCT Compound (Sakura, NL) or cryostat sections from patients with renal cell carcinoma, malignant melanoma or colon carcinoma were transferred to 3-10 ml of cold RPMI or PBS with 200IU/ml penicillin and $200\text{ }\mu\text{g/ml}$ streptomycin (RPMI/PEST, PBS/PEST) (Gibco BRL) and kept on ice. The tissue was washed three times by centrifugation and resuspension in 3-
- 35 10 ml cold RPMI/PEST or PBS/PEST. The pelleted, washed tissue was cut into pieces of approximately the same size and each piece was homogenised using a Mikro-Dismembrator U (B. Braun Biotech International, GE). The tissue was transferred to a PTFE shaking flask together with 1 ml RPMI/PEST or PBS/PEST and a tungsten

carbide grinding ball and homogenised during 15-20 seconds with a shaking frequency of 1500-2000 RPM. The homogenised tissue suspension was transferred to a test tube and kept on ice.

- 5 Extraction of preformed immunomodulating factors (PIF) from homogenised tumour tissue

Human tumour biopsies or cryostat sections were homogenised as described above. The homogenous tissue suspension was washed three times by centrifugation in a final volume of 1.5 ml, 10 ml or 23 ml cold PBS/PEST or RPMI/PEST, as appropriate.

- 10 The supernatants, containing PIF, was collected, pooled and kept on ice. PIF was then filtered through a 0.45 µm Millex-HV syringe filter (Millipore) and stored at -70°C. Before testing for monokine inducing activity in fresh, normal PBMC as described above, PIF was buffer exchanged to RPMI as described previously and filtered through a 0.45 µm Millex-HV syringe filter (Millipore).

15

Homogenised, washed tumour tissue incubated with matrix metalloproteinase-2. The collection, washing and homogenisation of tumour cryo sections (3 x 300 µm) were carried out as described above. The pelleted tumour tissue was suspended in 0.5 ml cold RPMI/PEST. MMP-2 (R&D Systems, UK), activated according to instructions from the manufacturer, was added at a final concentration of 5 ng/ml. The tumour tissue suspension was incubated with MMP-2 for 20 h at 37°C and the supernatant collected after centrifugation. Parallel incubation of tumour tissue with no addition of MMP-2 was set up as a control. The mixtures were buffer exchanged to RPMI by gel filtration through a Sephadex-G25 (PD-10) column (Amersham Biosciences, SE) and filtered through a 0.45 µm Millex-HV syringe filter (Millipore, MA, US). Finally, the mixtures were analysed by gel-electrophoresis and tested for monokine inducing activity in fresh normal PBMC as described above.

25

Homogenised tumour tissue and PIF incubated with serum albumin or IgG

- 30 The pelleted homogenised tumour tissue formed during preparation of PIF (see above) was kept on ice and stored at -70°C. PIF were prepared as described above. In one experiment, the homogenised sections were washed once more to collect a fourth supernatant, used as a control reflecting the IL-6 inducing activity in tumour sections before incubation. The fourth supernatant was divided into two parts, to one of which was added 20 mg/ml of HSA and directly frozen at -70°C. The mixtures of homogenised tumour tissue with 20 mg/ml HSA or with 10 mg/ml pooled human IgG for intravenous injection (IvIg), as well as the mixtures of PIF with 20 mg/ml HSA or with 10 mg/ml IvIg, all in RPMI/PEST, were incubated for 18-21.5 h at 37°C. Parallel
- 35

incubations of tumour tissue and PIF with no addition of HSA or IvIg, as well as RPMI/PEST with addition of HSA or IvIg, were set up as controls. The mixtures were centrifuged and supernatants collected. The supernatants were buffer exchanged to RPMI as described previously and filtered through a 0.45 µm Millex-HV syringe filter (Millipore, MA, US) and stored at -70°C until testing for monokine inducing activity in fresh, normal PBMC as described above.

Statistical Analysis

Comparisons of the means of different patient groups or different test occasions were performed using an unpaired t-test. Time to progression and survival was analyzed using the Kaplan-Meier method and Logrank test.

Comparisons between the proliferative response to PHA in different groups or at different test occasions were done on logarithmated mean values of dpm of triplicates using unpaired t-test. For the determination of the effect of addition of CHL on the proliferative response of PHA-stimulated PBMCs, a modulation index (MI) was calculated according to the following formula:

$$MI = \log (dpm \text{ PHA} + \text{drug}/dpm \text{ PHA}).$$

RESULTS ON IMMUNOREGULATORY MECHANISMS OF RELEVANCE FOR THE PRESENT INVENTION

Demonstration of intratumoural IL-1Ra

As described above IL-1Ra is a potent inhibitor of immune stimulation/reactivity as it blocks the activity of IL-1. It is therefore of considerable importance that it is frequently expressed by tumour cells and tumour infiltrating mononuclear cells.

Based on the results presented in the above, it is highly reasonable to assume that tissue bound IgG is the inducer of this cytokine. Thus either tissue bound antibodies or intra-tumourally precipitated ICs can play a major role in intra-tumoural down-regulation of the immune response. FIG. 1 shows melanoma biopsies stained for the expression of IL1Ra. Different patterns are hereby found, viz. A) tumour cells are generally stained with some positive infiltrating mononuclear cells, and B) large numbers of infiltrating cells staining for IL-1Ra, tumour cells only faintly positive.

Production of IL-1Ra in cultures of PBMC

Production of IL-1Ra can be induced by some cytokines (Tilg et al., 1994), but FcγR cross-linking by solid phase IgG or ICs seems to be the most efficient inducer of this substance. It has been shown that in cultures where binding of IgG to the surface of the culture well is allowed (uncoated wells) the production of IL-1Ra is significantly enhanced ($p < 0.0001$) compared to cultures where binding of IgG has been reduced

by pre-coating with HSA. This immunomodulatory effect has been studied in healthy individuals, patients with malignant melanoma and renal cell carcinoma (FIG. 2). If purified human IgG is added to the HSA in coated wells (HSA/IgG), IL-1Ra production by control PBMC is restored. Based on these results it is obvious that solid phase IgG will play a major role in immune regulation.

In cultures where the wells have been pre-coated with HSA (FIG 3A) a significant difference in IL-1Ra production was found between PBMCs from normal healthy individuals (K; n=46) and melanoma (MM1; n=43) and renal cell carcinoma patients (RCC 1; n=37) with metastatic disease ($p = 0.017$ and $p < 0.008$, respectively). In melanoma patients with radically resected stage III disease (MM 0; n=29) there was only a slight increase in IL-1Ra production. These results provides evidence for an immunomodulating role of cell bound IgG/ICs and that sera from cancer patients contain factors which are bound to PBMCs and are more potent in inducing IL-1Ra than serum factors from normal healthy individuals. It is reasonable to believe that this serum factor is comprised of complexed IgG. In cultures where PBMCs are exposed to solid phase serum IgG (FIG. 3B, uncoated wells) the production is significantly increased as described above and differences between healthy individuals and cancer patients are masked.

The occurrence of tissue bound IgG exposing the Fc-parts, in tumour tissue inducing production of IL-1Ra as described herein is thus highly relevant to the down-regulation of the anti-tumour immune reactivity.

Inhibition of IL-1Ra production by anti-CD32 fragments.

Based on the results described above blockade of the receptor(-s) involved in the induction of IL-1Ra production is a therapeutic strategy. It is demonstrated that pre-incubation of PBMCs from normal, healthy individuals and cancer patients with an anti-CD32 Fab fragment before these cells were set up in cultures on either uncoated or HSA/IgG coated microtitre plates significantly inhibits the production of this cytokine.

Table 1.

Effect of antibodies to FcγR II, anti-CD32 Fab, on IL-1Ra production by normal PBMC

	Anti-hu CD32 Fab effect on cultured PBMC on uncoated culture plates			Anti-hu CD32 Fab effect on cultured PBMC on HSA/IgG precoated culture plates		
	None	Anti-hu CD32, 5 µg/ml	Anti-hu CD32, 50 µg/ml	None	Anti-hu CD32 5 µg/ml	Anti-hu CD32 50 µg/ml
Ctrl 1 ¹⁾	N.D. ⁴⁾	N.D.	N.D.	6275	N.D.	2210
Ctrl 2	2985 ³⁾	N.D.	725	6620	N.D.	1530
Ctrl 3	4905	2380	560	3075	925	570
Ctrl 4	6014	N.D.	1926	4969	N.D.	1782
Ctrl 5	N.D.	N.D.	N.D.	>10 000	N.D.	5824
Ctrl 6	N.D.	N.D.	N.D.	>10 000	N.D.	>10 000
Pat. 1 ²⁾	4330	3095	2200	4195	1520	630
Pat. 2	1180	700	685	1170	735	910
Pat. 3	2870	1415	870	1350	340	180
Pat. 4	>10 000	N.D.	3260	N.D.	N.D.	N.D.

¹⁾ Control PBMC from healthy donors5 ²⁾ PBMC from cancer patients³⁾ IL-1Ra, pg/ml⁴⁾ Not done

Note: All PBMCs were pre-incubated with anti-human CD32 Fab 1.0 hr, 37°C before culturing.

10

Thus various strategies, which interfere with the cross-linking of the IL-1Ra inducing Fc receptor, are the base of therapeutic strategies, which will relieve immunosuppression and thereby improve the prospect for successful immunostimulating treatment.

15

Modulation of FcγR activity by protease inhibitors

It has been demonstrated that proteolytic activity increases the reactivity of FcγRII (Isashi et al., 1998 ; van der Winkel et al., 1989). The proteolytic activity is enhanced in malignant tumours; thus protease inhibitors will reduce the reactivity of CD32. Herein it is demonstrated that culturing PBMCs in the presence of non-toxic concentrations of a protease inhibitor, Tosyl, resulted in a significantly reduced

20

production of the immune inhibitory cytokine IL1Ra. Thus inhibition of intra-tumoural proteolytic activity offer an excellent therapeutic strategy for treating cancer. FIG 4 shows inhibition of IL1Ra production by Tosyl. The effect of Tosyl on IL-1Ra production by PBMC from healthy individuals (n=9) in 10% autologous sera cultured in microtiter plates pre-coated with A) HSA, and B) HSA/IgG.

Immunostimulation by FcγR cross-linking

It is demonstrated herein that PBMC cultured on HSA/IgG coated microtitre plates have a dramatically enhanced proliferative response to IL-2 in both normal healthy individuals and cancer patients compared to cultures in HSA coated wells. A similar effect is found when cultures, where IgG from serum in the culture medium is allowed to bind to the microtitre plates (uncoated cultures) and HSA coated cultures are compared. FIG. 5 shows IL-2 induced proliferation by PBMC from normal healthy individuals (first three bars) and PBMC from RCC patients (last three bars) cultured in 10% autologous sera on uncoated and pre-coated microtiter plates. Significant ($p < 0.011$) difference in proliferation between PBMC from healthy individuals and RCC patients on uncoated plates.

As the same effect on IL-2 induced proliferations are seen in HSA/IgG coated cultures and uncoated cultures; this effect is due to the same mechanism. Solid phase IgG results in a broad cross-linking, which can elicit stimulation of the immune response in normal healthy individuals by eliciting a cytokine cascade including TNF-α and IL-1, which sensitises the response to IL-2 (increased numbers of receptors). This model reflects the situation when opsonised antigens or large ICs elicits an immune response. In HSA coated wells this stimulatory cross-linking can not take place, which results in a significantly lower response to IL-2. Alternatively, the difference in IL-2 induced proliferative response can be due to an immunomodulatory effect by the cross-linking per se and not a stimulatory cytokine cascade. Inhibitory signals in monocytes/macrophages might be overcome by broad cross-linking of FcγR.

In cancer patients stimulation by FcγR cross-linking (uncoated cultures) does not properly support the proliferative response to IL-2, as demonstrated above. The type of cytokines produced can be inhibitory and does not support an optimal response to IL-2. Preliminary data suggests that serum factor(-s) is of importance for the reduced response of PBMCs from cancer patients in uncoated cultures (FIG. 6).

Effect of FcγR blockade on IL-2 stimulated proliferation

The stimulatory effect in HSA/IgG coated cultures is to various degree inhibited by F(ab')₂ Mabs directed to FcγRs, in particular to FcγR I (CD64). This can reflect the effect of small inhibitory ICs.

5 Table 2.

Inhibition of IL-2 induced proliferation of PBMC with F(ab')₂ monoclonal antibodies against Fc receptors.

Experiment 1

Anti-FcRec Mab	Coat HSA	Uncoated	Coat HSA/IgG
None	30 361 1)	65 030	146 337
Anti-CD16	62 072	84 173	109 417
Anti-CD32	35 106	82 628	126 363
Anti-CD64	30 526	3 219	25 533

10 Experiment 2

Anti-FcRec Mab	Coat HSA	Uncoated	Coat HSA/IgG
None	16 315 ¹⁾	97 446	102 863
Anti-CD16	10 315	39 023	97 572
Anti-CD32	26 976	56 226	93 153
Anti-CD64	19 634	35 620	45 858

1) 3H-Thymidine uptake in counts per minute (cpm) on day 7. Mean of triplicate wells.

Background in wells without IL-2 did not exceed 750 cpm.

- 15 Flow cytometry was performed to verify binding of the F(ab')₂ monoclonal antibodies to PBMC. The inhibitory anti-CD64 antibodies bound to a higher percentage of monocytes than anti-CD16, but fewer monocytes than anti-CD32 antibodies, in both experiments. Furthermore, the mean fluorescent intensity of both anti-CD16 and anti-CD32 binding was higher than anti-CD64 in both experiments.
- 20 Thus, increased binding of the anti-CD64 F(ab')₂ antibody, compared to anti-CD16 and anti-CD32 does not explain the inhibitory effect.

Effect of FcγR cross-linking on the production of IL-6 in cultures of PBMC

These results follow under the discussion of modulation of IL-6 production.

25

The culture model described above provides for excellent opportunities of studying immunosuppressive regulatory mechanisms in cancer patients.

Cell bound IgG/ICs in tumor tissue and on PBMCs from cancer patients

As IC in cancer patients cause dys-regulation of the immune system, it is important, using suitable diagnostic tools, to identify patients with this kind of dys-regulation in order that patients, who are most likely to respond to therapeutic strategies based on elimination of FcγR inhibitory signals, can be selected. In this context determination of cell-bound ICs (CBIC) is the important invention as these might very well have full activity even in the absence of CIC (circulating immuno complex).

CBIC can be directly demonstrated by means of

- 10 IgG⁺ PBMC (peripheral blood mononuclear cells)
- IgG⁺ TIMC (tumour infiltrating mononuclear cells, demonstrated in surgical or fine needle biopsies, FNA)

CBIC can also be demonstrated by means of functional parameters such as

- 15 production of O₂⁻
- down-regulation of the ζ-chain of TCR
- down-regulation of CD80 and/or CD86
- Induction of IL-1Ra, demonstrated in biopsies and FNA
- induction of other monokines,

- 20 whereby a number of these parameters can be demonstrated immunohistochemically.

Immune complexes (ICs) can be determined in different ways. Standard methods for determining circulating ICs (CIC) are by indirect non-functional parameters as complement binding and activation, PEG-precipitation, phagocytosis, platelet aggregation.

Determination of CIC, to obtain prognostic information or to diagnose possible occurrence of ICs modulating the immune system, is likely to be irrelevant, as IC has to be bound to cellular receptors to have any immunomodulatory effect. Thus CBIC will have full immunomodulatory effect long before the amount of ICs is enough to saturate these receptors and ICs appear in the circulation. In the present case direct methods has been used to demonstrate the presence of cell/tissue bound IgG or ICs.

35 Two methods based on the binding of either a monoclonal antibody or protein G to the Fc part of IgG were used to demonstrate the occurrence of tissue bound IgG or IC. The Mab was directed to the Fc part of all subclasses of human IgG and protein G was genetically modified, binding only to the Fc part of IgG. Thus CBIC can be

demonstrated using flow cytometry, or CBIC on blood cells has been demonstrated using immunocytochemistry (IHC) on cytospin preparations. Further CBIC has been demonstrated in tumour tissue (tumour cells, endothelium, tumour infiltrating inflammatory cells) using IHC.

5

If the immunohistochemical distribution pattern of stained IgG/IC exclusively coincides with the pattern of the low affinity receptors for IgG (CD16 and CD32) the identified substance is considered being IC. Otherwise it is not possible to discriminate between IgG and IC as the monoclonal antibody and protein G might be able to bind to monomeric IgG as well. However, if IgG is bound to the tissue directly or in IC might be of minor importance as it will anyhow be recognised as "solid phase" IgG.

10

Immunocytochemistry of tumour tissue

15

20

25

30

Several quite different staining patterns have been found in biopsies from untreated and treated melanoma metastases. In the majority of untreated and treated metastases with a poor infiltration of inflammatory cells and with no or only minor tumour regressive changes IgG was found in perivascular areas of the intra-tumoural micro-vessels. In these patients - tumours - the endothelial cells of larger vessels were stained indicating a systemic distribution of IC as endothelial only express CD32 and the bound IgG has to be in the form of complexes. FIG. 7 shows tumour biopsies stained for the presence of tissue bound IgG/IC (red) and T-lymphocytes (brown) using a double staining technique with recombinant protein G (not binding to albumin). Different staining patterns are shown, viz. A) staining of vascular areas/endothelial cells and some lymphocytes for IgG. Some lymphocytes are not stained for IgG/IC. Low numbers of tumour infiltrating mononuclear cells, B) a diffuse staining of the tumour tissue for IgG/IC, whereby the majority of the lymphocytes are not stained for IgG/IC, C) staining tumour infiltrating macrophages and some lymphocytes for IgG/IC, but tumour cells are generally negative, D) extensive staining of vascular areas for IgG/IC with very low numbers of infiltrating mononuclear cells.

35

These results show that tissue bound IgG exposing Fc parts, are inversely correlated to the presence of tumour infiltrating mononuclear cells and hence plays a major role in the down-regulation of the immune response to the tumour.

Immunocytochemistry of PBMC

Based on the results described above the occurrence of IC binding circulating blood cells was studied in cytopsin slides stained using the two methods described.

Preliminary results show that a very low frequency of positive monocytes was found in the majority of healthy individuals in contrast to patients with cancer. As
5 monocytes from healthy individuals were generally negative the stained IgG represents IC indicated by the staining of platelets. (FIG. 8).

Chronic inflammatory reaction in cancer using IL-6 as a marker

Chronic inflammatory reaction is often found in cancer patients. Interleukin-6 is a
10 proinflammatory cytokine of importance for the initiation of immune reactivity (Barton, 1996; Barton, 2001). However, in cancer patients, its occurrence has a number of detrimental effects. Inflammatory cells, vascular endothelium and several types of tumour cells produce it. It has activity as autocrine growth factor in at least some malignancies, e.g., myeloma and renal carcinoma. It can interfere with the
15 cytotoxic activity of cisplatin (Borsellino et al., 1995; Mitzutani et al., 1995). It participates in the induction of acute phase reactants, e.g., fibrinogen and CRP. In this context it can be involved in a positive regulatory loop as the production of fibrin split products have been found to be inducers of IL-6. This is one of the cytokines, which seems to be involved in the paraneoplastic syndrome of cancer patients and
20 high serum levels of this cytokine are often associated with poor response to immunotherapy. Besides, these cytokines are not produced in healthy individuals. In cancer patients, however, PBMCs (as shown above) are triggered to produce considerable amounts of IL-6 in vivo and continue to do so also in vitro. Except for cytokines, such as IL-1 β , IL-17 and TNF- α , a cross-linking of Fc γ R is a mechanism by
25 which monocytes are triggered to produce IL-6. Thus, CBIC is of importance for the dys-regulation of the immune system in cancer.

Various cytokines, IL-1 β , IL-6, TNF- α , PGE₂, TGF- β are often increased in cancer patients. (Mocellin et al., 2001) Several of these IL-1 β , IL-6, and TNF- α are supposed
30 to be involved in the paraneoplastic syndrome characterized by low-grade fever, anorexia, weight-loss, and fatigue. An increased systemic concentration of IL-6 has been reported to correlate with a poor prognosis and poor response to chemotherapy (Borsellino et al., 1995; Mitzutani et al., 1995). Furthermore, it is well documented that patients with high IL-6 serum levels (increased CRP) can not be successfully
35 treated with immunotherapy. (Blay et al. 1992; Deehan et al., 1994; Lissoni et al., 1999; Tartour et al., 1996).

PGE₂ is well known to be a potent inhibitor of immune reactivity. Thus patients with high serum levels of PGE₂ before treatment or having an increased production of PGE₂ during the early treatment period will not respond to immunotherapy. (Deehan et al., 1994)

5

An increased production of O₂⁻ radicals by monocytes has been demonstrated to down-regulate the ζ-chain of the T-cell receptor resulting in a non-functional state of these cells. (Kono et al., 1996; Otsuji et al., 1996)

- 10 Therapeutic control of the dys-regulatory mechanisms of IL-6 production will thus improve quality of life, therapeutic response to immuno- and chemotherapy, and increase over-all survival.

- 15 As IL-6 is only one product of the dys-regulated inflammatory reaction mentioned, and often correlates to production of the other cytokines such as IL-1β and TNF-α, the strategy is to find the fundamental dys-regulatory mechanisms and block them in order to completely down-regulate the inflammatory reaction.

IL-6 production in cancer patients, correlation to prognosis

- 20 The present analysis includes IL-6 production from PBMCs from three types of cancer patients. As shown in Table 3, 30 patients with radically resected stage III melanoma (MM0), 43 patients with previously untreated metastatic melanoma (MM1), 36 with previously untreated metastatic renal cell carcinoma (RCC1) and 46 patients with primary colorectal cancer (CRC) were studied. The cytokine production is, compared to that of healthy individuals (K), significantly increased in all categories. It is obvious that IL-6 production is not restricted to patients with advanced disease as IL-6 is produced also by PBMCs from patients with primary colorectal cancers and radically resected stage III melanoma (MM 0), whereby in the latter group no metastatic lesions could be demonstrated by clinical or radiological investigations. A correlation between IL-6 production by PBMCs and other clinical parameters was demonstrated for colorectal cancer and renal cell carcinoma.
- 25
- 30

- 35 The serum concentration of IL-6 was determined in melanoma, colon and renal cell carcinoma patients and was generally below the detection limit of the ELISA-technique used. In only a few cases measurable amounts of IL-6 were found but these were quite negligible compared to those found in cultures.

Table 3

Production of IL-6 by PBMCs from healthy individuals and various types of cancer patients.

Group	No of patients	Mean value pgIL-6/ml	+SE	t-test compared with controls
K	49	214	85	-
MM 0	30	2444	978	p>0.0001
MM 1	43	3838	1279	p>0.0001
RCC 1	36	4003	935	p>0.0001
K	12	379	133	-
CRC	46	5973	1362	p = 0.042

5

Colorectal cancer

As shown in FIG. 9, the IL-6 production increases with more advanced primary tumour, the difference between T2N0 and T3-4N0 achieved statistical significance after stimulation with bacterial lipopolysaccharide (LPS) ($p = 0.05$). Also the lymph node status had an impact on the production of this cytokine with higher IL-6 production by PBMCs from patients with lymph node metastases ($p = 0.02$). FIG. 9 shows the production of IL-6 by PBMCs from different subsets of colorectal cancer patients, viz. A), without LPS stimulation and B) with LPS stimulation.

15 In renal cell carcinoma IL-6 production is of prognostic significance as evident from FIG. 10. Patients that produced < 2500 pg/ml IL-6 in short term cultures ($n=18$) showed significantly longer survival than patients that produced > 2500 pg/ml ($n=23$).

20 Effect of Fc γ R cross-linking on IL-6 production by PBMCs in vitro

The culture conditions have a marked impact on the production of IL-6. If IgG from serum in the culture medium was allowed to bind to the surface of the culture wells, the IL-6 production was significantly lower, compared to cultures, wherein the wells were pre-coated by HSA, in about one third of the patients with malignant melanoma and colorectal cancer (both malignancies analysed together, $p = 0.001$).

25

The inhibitory effect of Fc γ R cross-linking was further demonstrated in PBMC cultures from healthy individuals wherein the culture wells were either pre-coated with HSA/IgG or HSA alone. Also in this situation, solid phase IgG significantly reduced

the production of IL-6 by PBMCs from some individuals (FIG. 11). FcγR cross-linking induced by solid phase IgG thus inhibits production of IL-6 in some patients.

5 The occurrence of this phenomenon in cultures with PBMCs from healthy individuals, as well, is not surprising, as this evidently is one of the normally occurring immunoregulatory mechanisms, the magnitude of which is increased in cancer patients. The difference between patients with and without this type of inhibition is evidently due to triggering of the monocytes or due to the influence of other factors. One explanation may be that a high concentration of a serum factor can induce IL-6
10 production despite the inhibitory action of FcγR cross-linking. At low concentrations of this factor, the inhibitory action of FcγR cross-linking will take over.

The evidence given shows the interaction of the two immunoregulatory mechanisms described herein based on the analysis of the results of the different experiments
15 carried out.

Occurrence and characterisation of a serum factor inducing IL-6 production by PBMCs
Production of IL-6 by PBMCs from in particular cancer patients in vitro, means that either are the producing cells triggered in vivo and maintain this status when placed
20 in culture or there is a serum factor which continuously stimulates production of IL-6. In order to discriminate between these two alternatives, sera from cancer patients, with a high IL-6 production in autologous PBMC cultures, were used in the medium of five cultures with PBMCs from healthy individuals. A high IL-6 production was induced in all these cultures demonstrating occurrence of an IL-6 inducing serum
25 factor.

Table 4

IL-6 inducing activity in sera from cancer patients cultured with PBMCs from healthy individuals with blood group 0.

Sera	IL-6, pg/ml
Patient 1	13129
Patient 2	2440
Patient 3	5313
Patient 4	4951
Patient 5	25276
Control 1 ¹⁾	31.2
Control 2	31.2
Control 3	31.2
Patient 6 ²⁾	115
Patient 7 ²⁾	31.2

5 ¹⁾ Control from healthy individuals

²⁾ Sera from patients who did not produce IL-6 in vitro

None of the control PBMC made detectable amounts IL-6 when cultured with autologous, normal sera.

10 Effect of ProteinG-Sepharose affinity chromatography of sera on IL-6 inducing activity

As cancer patients have an increased incidence of CIC and as it has been shown that cross-linking of FcγR can induce IL-6 production by monocytes, the IgG fraction was removed from these sera using affinity chromatography with proteinG-Sepharose.

15 When sera treated in this way were tested in cultures with PBMCs from the same healthy individuals, the IL-6 production was not only maintained but also even increased.

Table 5.

Effect of ProteinG-Sepharose affinity chromatography of sera on IL-6 inducing activity

	Autologous sera		Patient sera 1 (CC ¹)		Patient sera 2 (CC)		Patient sera 3 (MM ²)	
	-	Prot G		Prot G	-	Prot G	-	Prot G
Control PBMC 1	< 31.2 ³	N.D. ⁴	5313	8599	4951	12648		
Control PBMC 2	< 31.2	N.D.	9551	15243	13099	18618		
Control PBMC 3	< 31.2	< 31.2					25276	30316
Control PBMC 4	< 31.2	< 31.2					11342	12806

¹ CC = colon carcinoma

² MM = malignant melanoma

³ pg/ml of IL-6

⁴ N.D. = not done

Patient sera 3 did not contain detectable, endogenous IL-6. Patient sera 1 and 2 were not tested for endogenous IL-6.

Thus, CIC are not involved in inducing IL-6 production, but either CIC or IgG obviously modulate the production as it increased when IgG was removed from the culture medium. This is compatible with the results above where FcγR cross-linking by solid phase IgG inhibited IL-6 production. When IgG is removed from the culture medium, the inhibitory effect is relieved. Affinity chromatography with proteinG-Sepharose had no effect on control sera not inducing IL-6 production. Determination of IgG after affinity chromatography did not find detectable amounts of IgG (< 0.01 mg/ml).

Characterisation of IL-6 inducing factor (IL-6IF) by ultrafiltration

In order to confirm that CIC are not the inducer of IL-6 production by PBMCs in cancer patients and also to further characterise the IL-6 inducing factor, sera from cancer patients and healthy individuals were diluted (1:5) and ultrafiltered with a filter cut-off at 100, 50 and 3 kD. In some analyses only a factor with a molecular weight of less than 50 kD was identified, whereas in others IL-6IF was at least to some extent also found in the other fractions, but this activity could always be

demonstrated in the less than 50 kD fraction. IL-6 inducing activity was generally not found in the fraction with a molecular weight of less than 3 kD. These results show that IL-6IF has a low molecular weight and thus IgG or CIC can not be involved. The occurrence of this factor in some experiments, also in fractions having a molecular weight >50 kD, indicates either that the IL-6 inducing activity can depend on molecules of different sizes or that a small factor is bound to other serum proteins. The former case is compatible with the assumption that this factor is a proteolytic fragment of some large molecule, and that the activity is present in fragments of different sizes. If the IL-6IF were a small fragment it is certainly likely that it is bound to other serum proteins as it would otherwise immediately be excreted in the urine.

Table 6.

Activity of ultrafiltered serum fractions

	Activity of ultrafiltered serum fractions from cancer patients that previously had a stimulating effect on autologous cells and control serum from healthy individuals		
	unfiltered	< 50 kD ¹⁾	< 3 kD
Control sera 1 ²⁾	<31.2 ³⁾	461	101
Control sera 2	<31.2	394	40
Control sera 3	<31.2	74	42
Patient sera 1 ⁴⁾	<31.2	1264	43
Patient sera 2	<31.2	1404	<31.2
Patient sera 3	34	212	<31.2
Patient sera 4	13 129	9480	N.D. ⁵⁾
Patient sera 5	2440	986	N.D.

1) Size of ultrafiltered proteins

2) Control serum from healthy individuals

3) IL-6, pg/ml

4) Serum from cancer patients with malignant melanoma

5) N.D. = not done

(Note: All serum fractions were cultured with PBMC from healthy individuals with blood group 0. None of the serum fractions had IL-6 activity when cultured without PBMC)

The fractions obtained during ultrafiltration of sera described above were also analysed using PAGE electrophoresis of reduced proteins. In the fractions with the highest IL-6 activity a band having a molecular weight of about 20 kD was identified. This was either very weak or not present in all fractions of control sera or patient sera with no IL-6 inducing activity.

Affinity chromatography of serum using gelatine-Sepharose

To further characterise the IL-6IF and also to demonstrate a possible similarity to the "immunesuppressive factor" described by others (Easter et al., 1988; Hoyt et al., 1988) its binding to gelatine-Sepharose was studied. Despite a surplus of the binding gel, IL-6 inducing activity was not reduced when serum, prepared in this way was tested in cultures with control cells.

IL-6 Inducing activity in urine

As IL-6IF was found to have a molecular weight of less than 50 kD, it is assumed that this factor will at least, to some extent be excreted in the urine. Thus the less than 50 kD fraction was prepared and concentrated using the 3 kD filter. When these fractions from cancer patients were tested for IL-6 production in cultures with PBMCs from healthy individuals an IL-6 inducing activity was found.

Table 7

IL-6 inducing activity in ultrafiltered fractions (3 to 50 kD) from urine of cancer patients and healthy individuals

Urine from	Control PBMC 1	Control PBMC 2	Control PBMC 3	Control PBMC 4
Patient 1 (RCC ¹)	1053 ²			
Patient 2 (RCC)		>2000		
Patient 3 (RCC)		1716		
Patient 4 (RCC)		>2000		
Patient 5 (MM ³)		>2000		
Control 1			698	291
Control 2			-	497

¹ RCC = Renal cell carcinoma

² IL-6, pg/ml

³ MM = malignant melanoma

None of the control PBMCs produced detectable amounts (<31.2 pg/ml) of IL-6 when cultured without urine fractions.

5

The identification of IL-6IF, or any other inducing factor of an immunoregulatory substance, in the urine opens interesting diagnostic and therapeutic possibilities. When concentration of IL-6IF of urine is related to the serum concentration a simple diagnostic test is made which provides essential information about prognosis and the likelihood of therapeutic success. The diagnosis will also be of value to determine treatment strategies dealing with the elimination of IL-6IF - treatment of the chronic inflammatory reaction in cancer patients.

10

IL-6 inducing activity in tumour extracts

15

The origin of IL-6IF is so far unknown. However, it is related to the presence of a malignant tumour. The observation that IL-6IF has a low molecular weight is compatible with its being an enzymatic fragment of some large molecule. It is assumed that this factor is produced in the tumour or by substances released from the tumour. In order to verify this, tumours were minced using a stainless steel mesh and extracted in physiological buffer during various times. In fact, 5 out of 7 analysed tumours produced the factor when the extracts were tested in cultures of PBMCs from healthy individuals. These findings are in agreement with the increased enzymatic activity of tumours as well as the poor prognosis of patients with a high expression of several proteolytic enzymes.

20

Table 8.

IL-6 inducing activity in extracts from frozen tumour biopsies and fresh tumour

Tumour extracts	IL-6 produced by control PBMC
CC 1	564 ¹⁾
MM1	313
RCC1	< 31.2
RCC 2	<31.2
RCC 3	1078
RCC 4	1025
RCC 5 ²⁾	1554

1) pg/ml

2) Fresh biopsy

30

None of the tumour extracts contained detectable endogenous IL-6 activity

None of the control PBMCs produced detectable amounts of IL-6 when cultured in autologous sera without tumour extracts.

All control PBMCs produced >1200 pg/ml of IL-6 when cultured in the presence of Lipopolysaccharide (LPS).

5

IL-6 inducing activity in conditioned culture media from tumour cell lines

Immunomodulating factors have been identified in large numbers at studies of either tumour extracts or conditioned culture media from tumour cell lines. It has now turned out that IL-6IF is produced by squamous cell carcinomas from the oral cavity.

10

Conditioned media were collected and tested using PBMCs from healthy individuals as described. An IL-6 inducing activity was demonstrated and this will facilitate studying therapeutic possibilities such as reduction of IL-6IF by inhibiting different types of tumour related enzymes, such as MMPs.

15

Table 9

IL-6 inducing activity in ultrafiltered (3 to 50 kD) condition media from a squamous cell carcinoma (SCC) cell line grown in media with fetal calf serum (FCS) or pooled human AB-sera from two different batches AB7, and AB8, respectively.

5

Conditioned media	Control PBMC 1	Control PBMC 2	Control PBMC 3	Control PBMC 4	Control PBMC 5	Control PBMC 6	No PBMC (endogenous activity)
UT-SCC-10 in FCS	1559 ¹⁾	925					<31.2
Media FCS, no cells	221	<31.2					<31.2
UT-SCC-10 in AB7			>2000	1753			287
Media AB7, no cells			939	718			<31.2
UT-SCC-10 in AB8					3043	6821	<31.2
Media AB8, no cells					<31.2	2975	<31.2

¹⁾ IL-6, pg/ml

Similar to the situation with IL-6 we have also found inducing activity for TNF- α and IL-1 β (Table 10) and IL-10 in serum and ultrafiltered urine. IL-10 was found in four sera/serum fractions and one urine fraction also inducing IL-6. In addition, one serum and one urine fraction inducing IL-6 did not induce IL-10.

10

Table 10

TNF- α and IL-1 β inducing activity in IL-6 inducing serum and ultrafiltered urine from cancer patients

Source	Control PBMC	IL-6 pg/ml	TNF- α pg/ml	IL-1 β pg/ml
Patient serum 1	None	<31.3	N.D.	N.D.
Patient serum 1	PBMC 1	13129	1774	414
Patient serum 2	None	<31.2	86	8
Patient serum 2	PBMC 2	153	153	14
Patient serum 2	PBMC 3	2440	762	136
Patient urine 1	None	<31.2	<31.2	<7.8
Patient urine 1	PBMC 4	>2000	123	147
Patient urine 1	PBMC 5	>2000	199	128
Patient urine 2	None	<31.2	<31.2	<7.8
Patient urine 2	PBMC 4	>2000	166	>500
Patient urine 2	PBMC 5	>2000	582	>500

5 N.D. = not done

None of the control PBMCs made detectable levels of IL-6, TNF- α or IL-1 β , when cultured in autologous serum.

Possibility to predict therapeutic response to drug therapy of cancer based on

10 induction of cytokines.

We have previously shown that an Immune status that correlates to response to immunotherapy can be identified by analysing the effect of immunomodulating drugs on PHA stimulated PBMCs from renal cell carcinoma patients. An increased proliferation in cultures where cimetidine is added identifies responders to interferon-
 15 alpha and a reduced proliferative response to chlorambucil identifies responders to interleukin-2 (Fig. 12). Now we demonstrated that there is a correlation between the effect of chlorambucil on the proliferative response to PHA and on the production of TNF- α in this type of cultures (Fig. 13). Thus, in non-responders TNF- α production is more stimulated than in responders. This opens up the possibility to analyse the
 20 pattern of inducing factors for these two subsets of patients and thereby identify responders to immunotherapy.

CHARACTERISATION OF DYSREGULATING FACTORS

Analysis of cytokine inducing factors in urine

As described above factors inducing IL-1 β , IL-6, IL-10 and TNF- α have been

5 identified in the 3-30 kD fraction in tumour extracts, conditioned culture media from cancer cell lines, and cancer patient sera and urine. These urine factors were further characterised by using 2D-gel electrophoresis and identified after fragmentation using massspectrometry and N-terminal sequence analysis.

10 Comparison between healthy controls and cancer patients

Comparisons were made between a pool of 11 healthy controls (control pool) and four individual controls and **1.** a pool of one breast and one pancreas cancer patient, **2.** a pool of two renal cell carcinoma patients and **3.** three individual melanoma patients.

15

Proteins or fragments of proteins found in the urine fraction from different types of cancer patients but not in healthy controls are shown in Table 11. Some proteins / fragments were found in the urine of several different cancer patients, e.g. albumin /albumin fragments, CD59, plasma retinol binding protein and prostaglandin D2

20 synthase

Inter-alpha-trypsin-inhibitor, fragment of chain 2	X		
Lithostathine 1 alpha			X
Plasma retinol binding protein		X	X
Prostaglandin D2 synthase	X	X	X
Secreted LY-6 /uPar related protein/Anti-neoplastic urinary protein	X		
Splice isoform 2 of tropomyosin alpha 3 chain			X
Zinc-alpha-2-glycoprotein, fragment of chain 3	X		

Comparison between urine fractions with and without IL-6 inducing activity

In order to further characterise and identify the cytokine inducing factors,

- 5 comparisons were made between urine samples from melanoma patients with and without IL-6IF activity. As shown in Table 12 several fractions were present in considerably higher amount in urine with IL-6 inducing activity.

Table 12.

Comparison between melanoma patients with and without IL-6 inducing activity.

Proteins over represented in urine fraction from patient with IL-6 inducing activity

Protein spot on 2D gel	Protein / protein fragment analysed by masspectometry	Alternative protein/s according to masspectormetry analysis
1	Beta-microsemino protein	
2	CD59	
3	CD59	
4	CD59	
5	Colipase	Inhibin beta
6	Extracellular superoxide dismutase	
7	Heparan sulphate proteoglycan (Perlecan)	
8	Immunoglobulin kappa light chain	
9	Immunoglobulin superfamily member 8	LIR-D1 precursor
10	IL-13 receptor alpha-1 chain	Urokinase plasmin activator surface
11	Inter-alpha-trypsin inhibitor, chain 2	Endoplasmic reticulum protein ERP29
12	Lithostathine 1 alpha	
13	Lithostathine 1 alpha	

5

Analyses of urine fractions before and after adsorption with PBMCs

Identification of inducing factors was next done in two experiments by adsorbing urine, containing IL-6IF, with purified PBMCs from healthy controls. The cells chosen for adsorption were shown to be stimulated to produce IL-6 by these urine fractions.

10 The IL-6 inducing activity was significantly reduced by the adsorption procedure (Table 13).

Table 13.

IL-6 and TNF-alpha inducing activity in adsorbed and unadsorbed urine fractions

5 Urine fraction pooled from two renal cell carcinoma patients

Urine fraction added to control PBMCs	IL-6			TNF-alpha		
	Control PBMC 1	Control PBMC 2	Control PBMC 3	Control PBMC 1	Control PBMC 2	Control PBMC 3
None	<31.2 ¹⁾	392	<31.2	<31.2	225	67
Unadsorbed	778	942	1433	74	207	179
Adsorbed	311	1031	620	<31.2	59	49

Urine fraction from a patient with malignant melanoma

Urine fraction added to control PBMCs	IL-6			TNF-alpha		
	Control PBMC 4	Control PBMC 5	Control PBMC 6	Control PBMC 4	Control PBMC 5	Control PBMC 6
None	167	<31.2	<31.2	94	121	<31.2
Unadsorbed	>2000	>2000	55	348	531	38
Adsorbed	1187	1365	<31.2	78	203	<31.2

1) pg/ml

The urine fractions did not contain endogenous IL-6 or TNF-alpha.

10

In agreement with this, several proteins disappeared or were found in significantly reduced amounts in the adsorbed fractions as shown in 2D-gel electrophoresis (Fig. 14 and 15). Reduction in the amount of the proteins was recorded visually and confirmed using densitometry. Adsorbed proteins were identified using

15 massspectrometry. In addition the amino acid sequence of nine proteins / fragments was determined using the Edman sequencing technique. The identified proteins are shown in Table 14 and 15. Amazingly, the majority of these fractions were found to be fragments of normally occurring proteins, such as IgG, β 2-microglobulin and serum albumin.

20

Table 14.

Proteins/protein fragments adsorbed from an IL-6-inducing urine fraction pooled from two patients with renal cell carcinoma by purified normal PBMC.

Spot	Protein	Sequenced	Fragment starting with position
1	Albumin fragment	No	NA
2	Albumin fragment	No	NA
3	Albumin fragment	No	NA
4	Albumin precursor	Yes	253
5	Albumin precursor	Yes	253
6	Albumin precursor	Yes	253
7	Albumin precursor	Yes	517
8	Albumin precursor	Yes	101
9	Alpha-1-microglobulin	Yes	21
10	Alpha-1-microglobulin	Yes	21
11	Beta-2-microglobulin	Yes	22
12	Beta-2-microglobulin	Yes	47
13	IgG kappa light chain	No	NA
14	IgG kappa light chain	No	NA
15	IgG kappa light chain	No	NA
16	Zinc-alpha-2-glycoprotein	No	NA

NA = Not applicable

Table 15.

Proteins/protein fragments adsorbed from an IL-6-inducing urine fraction from a patient with malignant melanoma by purified normal PBMC.

Spot	Protein	Alternative protein/s according to mass spectrometry analysis
1	Colipase chain 1	Inhibin beta B chain
2	CD59	
3	Extracellular superoxide dismutase	
4	IL-13 Receptor alpha chain 1	Urokinase plasminogen activator
5	Similar to cytokeratin 8	IgG heavychain v region, Cell division protein kinase, GMP reductase 2, Vacuolar protein sorting 26
8	Tumor endothelial marker 1 precursor	

5

As these fragments were identified based on their adsorption to PBMCs, demonstrating a high degree of binding, the occurrence of receptors for these protein fragments / peptides on normal PBMCs sensitive to IL-6IF can be postulated. As albumin and β 2-microglobulin do not normally bind to these cells, it can be further postulated that fragmentation of these proteins results in conformational changes exposing new structures with a specific binding to receptors on PBMCs. As demonstrated herein this results in modulation of the immune system. Thus, the basis for a quite new mechanism of immunomodulation in diseases characterised by a high proteolytic activity, e.g. inflammation and cancer, has been discovered.

10

15

In conclusion, a large number of fragments, which were not consistently present in urine from healthy control persons, were found in urine from cancer patients. A difference in low molecular weight urine fragments was found between two patients, the urine of whom was either IL-6 inducing or not. This might reflect a significant difference in tumour related proteolytic activity in these two patients. Furthermore, several of these fragments could be adsorbed by PBMCs and different fragments were adsorbed in the two experiments presented herein, again indicating a difference in tumour related proteolytic activity between different patients. As a large number of fragments are generated the further characterisation of dysregulatory inducing factors was done using preparative proteomics, allowing determination of functional

20

25

activity during preparation, that is after isoelectric focusing and preparative gel-electrophoresis.

Fragmentation of IgG and serum albumin using matrix metalloproteinases (MMP)

- 5 Based on the results described above on the binding of IgG and albumin fragments to PBMCs, IgG or serum albumin was incubated with MMPs under well-defined conditions. Two different buffer systems were used in these experiments (Fig. 16). The supernatants were analysed using gel-electrophoresis and their cytokine inducing activity was analysed in cultures with normal PBMCs. As demonstrated in Figure 16
- 10 several MMPs released fragments of IgG and serum albumin, which induced or modulated IL-6 inducing production. In particular, MMP- 1, -2, -3, -13 released active fragments from albumin and MMP-2, -3, -7 and -13 from IgG.

Immunomodulating activity of extracellular matrix substance (ECM) fragments

- 15 In another experiment, fragments of an extra cellular matrix substance, collagen, was added to IL-2 stimulated cultures of PBMCs from healthy donors. Commercially available collagen contained a large number of fragments and these fragments were found to have a strongly inhibitory effect on IL-2 induced proliferation (Fig. 17).

20 Extraction of cytokine inducing factors from tumour tissue

- We have, in this document, described that IL-6IF can be extracted from malignant tumours, e.g. malignant melanoma, renal cell carcinoma, colorectal cancer. These results were confirmed in a new series of experiments, where homogenised tumours were washed three times in PBS or RPMI in order to collect cytokine inducing factors
- 25 already present in the tumours, so called "preformed inducing factors" (PIF).

- The occurrence of cytokine inducing factors in these washings was determined in short term cultures with normal PBMCs. As shown in Table 16, a high IL-6 inducing activity was repeatedly found in the PIF-fractions. These fractions were then further
- 30 analysed using isoelectric focusing and preparative electrophoresis.

Table 16.

- Induction of IL-6 production in PBMCs from healthy blood donors by factor/s extracted from homogenised tumours by RPMI, so called preformed inducing factors, PIF. Two PIF fractions were tested on PBMCs from 9 and 14 controls, respectively. As
- 35 can be seen, these fractions efficiently induce production of IL-6 whereas cultures with the buffer, RPMI, alone showed no or only a very low inducing activity.

Table 16

Tumor PIF preparation	Control PBMCs	IL-6 production (pg/mL)		
		RPMI	RPMI + LPS	RPMI + PIF
1	1	<6,25	>400	>400
1	2	<6,25	>400	>400
1	3	<6,25	>400	>400
1	4	<6,25	>400	>400
1	5	<6,25	>400	>400
1	6	<6,25	>400	>400
1	7	<6,25	>400	>400
1	8	<6,25	>400	>400
1	9	<6,25	>400	>400
2	10	<6,25	>400	>400
2	11	14	>400	>400
2	12	35	>400	>400
2	13	13	>400	>400
2	14	<6,25	>400	>400
2	15	<6,25	>400	>400
2	16	<6,25	>400	>400
2	17	<6,25	>400	>400
2	18	20	>400	>400
2	19	217	>400	>400
2	20	38	>400	>400
2	21	21	>400	>400
2	22	14	>400	>400
2	23	109	>400	>400

- 5 Release of cytokine inducing factors by incubation of homogenised, washed tumour tissue with MMPs

In order to reduce the amount of preformed cytokine inducing factors (PIFs) present in the tumours, tissue sections / homogenates were thoroughly washed before addition of proteolytic enzymes, such as MMPs. The tumour sections / homogenates

- 10 were then incubated for 20 hours at 37°C. IL-6 inducing activity of the supernatants

was then analysed in cultures of normal PBMCs. As shown in Fig. 18, addition of MMP-2 modulated the release of IL-6 inducing activity. In gel electrophoresis of these supernatants, the albumin band was found to be better preserved in incubations, to which MMP-2 was added. This is reasonably due to an effect of MMP-2 on the degradation of enzymes degrading albumin. It can thus be concluded that MMPs can degrade tumour tissue substances into fragments with cytokine inducing activity. The effect of MMP-2 on the preservation of albumin in these incubations also demonstrates that proteolytic enzymes are involved in the regulation of the intra-tumoural proteolytic activity. A complex interaction of proteolytic enzymes is thus demonstrated and this results in generation and / or modulation of the production of dysregulatory inducing factors.

Increased production of cytokine inducing factors by addition of IgG or serum albumin to washed tumour homogenates / tissue sections.

In order to further explore the nature of immunomodulating substances / fragments in tumours and based on the observation, mentioned above, that fragments of albumin, IgG and β 2-microglobulin efficiently binds to normal PBMCs, we added albumin or IgG to thoroughly washed tumour sections / homogenates and incubated for 18-22 h at 37°C. It was then found that addition of IgG and in particular albumin markedly increased the production of cytokine inducing factors as determined in PBMC cultures (Fig. 19). In order to rule out that the effect of adding albumin to these incubations was due to a protective action, such as reducing loss because of proteolytic degradation or binding to plastic surfaces, albumin was added to fresh PIF-fractions and incubated at 37°C for 18 h. Compared to parallel incubations with no addition of albumin, the IL-6 inducing activity was lower when albumin was added, which shows that the markedly increased IL-6 inducing activity after adding albumin to washed homogenates is not due to any protective activity of albumin but rather that albumin acts as a substrate for intra-tumoural proteolytic enzymes. Thus it is demonstrated that immuno-modulating IgG and albumin fragments are produced in the intra-tumoural milieu.

Based on our previous results it might seem somewhat amazing that incubation of PBMCs with IgG fragments results in an increased production of IL-6 as pre-coating of culture plates with IgG from serum or an albumin/IgG mixture inhibited IL-6 production. A reasonable explanation to this apparent discrepancy in effect is that the IgG fragments manage to block the inhibitory effect natural IgG. Thus resulting in an enhanced pathological production of IL-6. This opens up interesting possibilities to modulate FcR mediated immune regulation.

Analysis and characterisation of immunomodulating factors in tumour extracts using
"preparative proteomics"

Further analysis of PIF-fractions by isoelectric focusing and preparative
5 electrophoresis has identified two fractions with IL-6 inducing activity, with different
pI. Preparative electrophoresis also identified two fractions, of different molecular
weight, with activity.

ABBREVIATIONS

- ALP; Alkaline phosphatase
APC; Antigen presenting cell
5 BSA; Bovine serum albumin
BSS; Hank's balanced salt solution
CBIC; Cell bound immune complex
CIC, Circulating immune complex
ConA; Concanavalin A
10 CRC; Colorectal carcinoma
CRP; C-reactive protein
CTL ; Cytotoxic T-lymphocyte
DAB; 3,3'-Diaminobenzidine
ECM; Extracellular matrix
15 ELISA; Enzyme linked immunosorbent assay
ESR; Erythrocyte sedimentation rate
FcR; Fc receptor
GAH; Goat anti-human IgG antibody
HSA; Human serum albumin
20 IC; Immune complex
IHC; Immunohistochemistry
ICAM-1; Intracellular adhesion molecule-1
IL-1 β ; Interleukin-1 β
IL-4; Interleukin-4
25 IL-6; Interleukin-6
IL-10; Interleukin-10
IL-12; Interleukin-12
IL-17; Interleukin-17
IL-1Ra; Interleukin-1 receptor antagonist
30 IL-6IF; Interleukin-6 inducing factor
LPS; Lipopolysaccharide
MHC 1; Major histocompatibility complex 1
MM; Malignant melanoma
MMP; Metalloprotease
35 NK-cell; Natural killer cell
PAP; Peroxidase anti-peroxidase
PBMC; Peripheral blood mononuclear cell
PBS; Phosphate buffered saline

- PFA; Paraformaldehyde
PGE₂; Prostaglandin E₂
PHA; Phytohemagglutinin A
RCC; Renal cell carcinoma
- 5 RIA; Radioimmuno assay
RtPCR; Reverse transcriptase polymerase chain reaction
SBR; Serum blocking factors
TAA; Tumour associated antigen
TAM; Tumour infiltrating macrophage
- 10 TBS; Tris buffered saline
TGF- β ; Transforming growth factor beta
Th1; T helper 1
Th2; T helper 2
TIL; Tumour infiltrating lymphocyte
- 15 TIMC; Tumour infiltrating mononuclear cell
TNF α ; Tumour necrosis factor α

REFERENCES

- Arend W P, Malyak M, Guthridge C J, Gabay C. 1998. Interleukin-1 receptor antagonist: Role in biology. *Annu Rev Immunol* 16:27-55.
- 5 Baldwin R W, Robins R A. 1976. Factors interfering with immunological rejection of tumours. *Br Med Bull* 32:118-123.
- Bansal S C, Bansal B R, Boland J P. 1976. Blocking and unblocking serum factors in
10 neoplasia. *Curr topics Microbiol Immunol* 75: 45-76.
- Barton B E. 1996. The biological effects of interleukin 6. *Med Res Rev* 16:87-109.
- Barton B E. 2001. IL-6-like cytokines and cancer cachexia: consequences of chronic
15 inflammation. *Immunol Res* 23:41-58.
- Beezhold D H, Personius C. 1992. Fibronectin fragments stimulate tumour necrosis factor secretion by human monocytes. *J Leuk Biol* 51:59-64.
- 20 Berger S, Ballo H, Stutte H J. 1996. Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro- and anti-inflammatory cytokines dependent on the antigen: antibody ratio. *Eur J Immunol* 26:1297-1301.
- 25 Blay J Y, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani J M, Moskovtchenko J F, et al. 1992. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. *Cancer Res* 52:3317-22.
- Blay J Y, Rossi J F, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T,
30 Favrot M. 1997. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. *Int J Cancer* 72:424-30.
- Borsellino N, Belidegrun A, Bonavida B. 1995. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated
35 cytotoxicity of human prostate carcinoma cell lines. *Cancer Res* 55:4633-9.

- Bowles Goldsmith E, Erickson B W, Thompson N L. 1997. Synthetic peptides from mouse Fc receptor (MoFcγRII) that alter the binding of IgG to MoFcγRII. *Biochemistry* 36: 952-9.
- 5 Deehan D J, Heys S D, Simpson W G, Broom J, Franks C, Eremin O. 1994. In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. *Br J Cancer* 69: 1130-5.
- Deo Y M, Graziano R F, Repp R, van de Winkel J G J. 1997. Clinical significance of IgG
- 10 Fc receptors and FcγR-directed Immunotherapies. *Immunol Today* 18:127-135.
- Dinarello C A. 1997. Induction of Interleukin-1 and Interleukin-1 receptor antagonist. *Semin Oncol* 24: S9-81- S9-93.
- 15 Easter D W, Hoyt D B, Ozkan A N. 1988. Immunosuppression by a Peptide from the Gelatin Binding Domain of Human Fibronectin. *J Surg Res* 45:370-375.
- Fridman W H, Teillaud J-L, Bouchard C, Teillaud C, Astier A, Tartour E, Galon J, Mathiot C, Sautes. 1993. Soluble Fcγ receptors. *J Leuk Biol* 54:504-512.
- 20 Gearing A J H, Thorpe S J, Miller K, Mangan M, Varley P G, Dudgeon T, Ward G, Turner C, Thorpe R. 2002. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. *Immunol Lett* 81:41-48.
- 25 Gadducci A, Cosio S, Fanucchi A, Genazzani AR. 2001. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. *Anticancer Res* 21:2941-7.
- Geissmann F, Launay P, Pasquier B, Lepelletier Y, Leborgne M, Lehuen A, Brousse N, Monteiro RC. 2001. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. *J Immunol* 166:346-52.
- 30 Gessner J E, Heiken H, Tamm A, Schmidt R E. 1998. The IgG Fc receptor family. *Ann Hematol* 76:231-48.
- 35

Ghafour B, Stahlbom B, tagesson C, Lindahl M. 2002. Newly identified proteins in human nasallavage fluid from non-smokers and smokers using two-dimensional gel electrophoresis and peptide mass fingerprinting. *Proteomics* 2:112-120.

- 5 Goldin A, Nicolin A Bonmassar E. 1980. Chemoteraphy immunogenicity. *Recent Results Cancer Res* 75:185-94.

Gupta R K, Morton D L. 1981. Possible clinical significance of circulating immune complexes in melanoma patients. In Saunders, Serrou, Rosenfeld and Denney eds. *Fundamental mechanisms in human cancer immunology*. Elsevier North Holland Inc. 305-320.

- 10

Heimdal J H, Aarstad H J, Olofsson J. 2000. Monocytes secrete Interleukin-6 when co-cultured *in vitro* with benign or malignant autologous fragment spheroids from squamous cell carcinoma patients. *Scand J Immunol* 51: 271-278.

15

Heimdal J H, Aarstad H J, Olsnes C, Olofsson J. 2001. Human autologous monocytes and monocyte-derived macrophages in co-culture with carcinoma F-spheroids secrete IL-6 by a non-CD14-dependent pathway. *Scand J Immunol* 53: 162-170.

20

Hellström K E, Hellström I. 1974. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumour antigens. In Dixon F J and Kunkel H G. Eds. *Advances in Immunology*. Academic Press. 209-277.

- 25 Hoyt D, Ozkan N, Ninnemann J, Hansbrough J, Pinney E, Wormsley S. 1988. Trauma peptide induction of lymphocyte changes predictive of sepsis. *J Surg Res* 45: 342-8.

Huber D, Philipp J, Fontana A. 1992. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumour cell-mediates immunosuppression. *J Immunol* 148:277-84.

30

Isashi Y, Yamashita T, Nagasawa S, Tanaka K, Murakami M, Uede T. 1998. The mechanism by which proteolysis enhances the ligand-binding activity of guinea pig type II Fc receptor for IgG (FcγRIIB). *J Biochem* 123: 959-67.

35

Katayama M, Kamihagi K, Nakagawa K, Akiyama T, Sano Y, Ouchi R, Nagata S, Hino F, Kato I. 1993. Increased fragmentation of urinary fibronectin in cancer patients

detected by immunoenzymometric assay using domain-specific monoclonal antibodies. *Clinica Chimica Acta* 217: 115-128.

- 5 Kirkwood J, Vlock D. 1984. Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. *Cancer Res* 44: 4177-4182.

- 10 Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R. 1996. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. *Eur J Immunol.* 26(6):1308-13.

- 15 Lin S-Y, Kinet J-P. 2001. Giving inhibitory receptors a boost. *Science* 291:445-86.

Lindahl M, Stahlbom B, Svartz J, Tagesson C. 1998. Protein patterns of human nasal and bronchoalveolar lavage fluids analyzed with two-dimensional gel electrophoresis. *Electrophoresis* 19:3222-9.

- 20 Lissoni P, Brivio F, Viviani S, Fumagalli L. 1999. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy? *J Biol Regul Homeost Agents* 13:110-4.

- 25 López-Moratalla N, del Mar Calonge M, López-Zabalza M, Pérez-Mediavilla A, Subirá M, Santiago E. 1995. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins. *Biochimica et Biophysica Acta* 1265: 181-8.

- 30 Ménétrier-Caux C, Bain C, Favrot M C, Duc A, Blay J Y. 1999. Renal cell carcinoma induces interleukin 10 and prostaglandin E₂ production by monocytes. *Br J Cancer* 79: 119-130.

- 35 Milas L. 2001. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumour radioresponse. *Semin Radiat Oncol* 11:290-9

Mizutani Y, Bonavida B, Kolshihara Y, Akamatsu K, Ohsugi Y, Yoshida O. 1995. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum

(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55:590-6.

5 Mocellin S, Wang E, Marincola F M. 2001. Cytokines and immune response in the tumour microenvironment. J Immunother 24:392-407.

10 Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari V M, Pyrhonen S. 2001. High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 11:157-66.

North R. 1985. Down-regulation of the antitumor immune response. Advances in Cancer Research 45:1-43.

15 Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. 1996. Oxidative stress by tumour-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 93:13119-24.

20 Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J. 2000. Escape mechanisms in tumour immunity: a year 2000 update. Crit Rev Oncog 11:97-133.

25 Pricop L, Redecha P, Teillaud J-L, Frey J, Fridman W, Sautès-Fridman C, Salmon J. 2001. Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 166: 531-7.

Ravetch J V, Bolland S. 2001. IgG Fc receptors. Annu Rev Immunol 19:275-90.

30 Sallh HR, Schmetzer HM, Burke C, Starling GC, Dunn R, Pelka-Fleischer R, Nuessle V, Kiener PA. 2001. Soluble cd137 (4-1bb) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol 167:4059-66.

35 Sheu B C, Hsu S M, Ho H N, Lien H C, Huang S C, Lin R H. 2001. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61:237-242.

Sjögren H O, Hellström I, Bansal S C, Hellström K E. 1971. Suggestive evidence that the "blocking antibodies" of tumour-bearing individuals may be antigen-antibody complexes. Proc Nat Acad Sci USA. 68:1372-5.

Sulitzeanu D. 1993. Immunosuppressiv factors in human cancer. *Adv Cancer Res* 60:247-267.

- 5 Sutterwala FS, Noel GJ, Salgame P, Mosser DM. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type I. *J Exp Med* 188:217-22.

- 10 Szabo G, Miller-Graziano C, Wu J H, Takayama T, Kodys K. 1990. Differential tumour necrosis factor production by human monocyte subsets. *J Leuk Biol* 47:206-216.

- 15 Szabo G, Kodys K, Miller-Graziano C. 1991. Elevated monocyte interleukin-6 (IL-6) production in immunosuppressed trauma patients. I. Role of FcγRI cross-linking stimulation. *J Clin Immunol* 11:326-335.

- 20 Takizawa T, Nishinarita S, Kitamura N, Hayakawa J, Kang H, Tomita Y, Mitamura K, Yamagami K, Horie T. 1995. Interaction of the cell-binding domain of fibronectin with VLA-5 integrin induces monokine production in cultured human monocytes. *Clin Exp Immunol* 101:376-382.

- 25 Tartour E, Blay J Y, Dorval T, Escudier B, Mosseri V, Douillard J Y, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman W H. 1996. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. *J Clin Oncol* 14:1697-703.

- 30 Tilg H, Trehu E, Atkins M B, Dinarello C A, Mier J W. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumour necrosis factor receptor p55. *Blood* 83:113-8.

- 35 Walther M M, Johnson B, Culley D, Shah R, Weber J, Venzon D, Yang J C, Linehan W M, Rosenberg S A. 1998. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. *J Urol* 159:718-22.

- van de Winkel J G J, van Ommen R, Huizinga T W J, de Raad M A H V M, Tuijnman W B, Groenen P J T A, Capel P J A, Koene R A P, Tax W J M. 1989. Proteolysis induces increased binding affinity of the monocyte type II FcR for human IgG. *J Immunol* 143:571-578.

Vlock D R, Kirkwood J M. 1985. Serial studies of autologous antibody reactivity to melanoma. J Clin Invest. 76: 849-854.

- 5 Wolf H M, Hauber I, Gulle H, Samstag A, Fischer M B, Ahmad R U, Eibl M M. 1996. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and Fc α R (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF- α) and IL-6 in human monocytes. Clin Exp Immunol 105:537-43.
- 10 Vose B M, Vanky F, Klein E. 1977. Human tumour-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating blood and lymph-node lymphocytes with autologous tumour cells. Int J Cancer 20:895-902.

FIGURE LEGENDS

FIG 1 shows melanoma biopsies stained for the expression of IL1Ra. Different patterns are hereby found, viz. A) tumour cells are generally stained with some positive infiltrating mononuclear cells, and B) large numbers of infiltrating cells staining IL-1Ra, tumour cells only faintly positive.

FIG. 2 shows production of IL-1Ra in short term cultures of PBMC from healthy controls and cancer patients. The effect of pre-coating of the culture wells is shown.

FIG. 3 shows comparison of IL-1Ra production by PBMCs from healthy individuals and melanoma and renal cell carcinoma patients, cultured in A) HSA pre coated wells or B) uncoated wells.

FIG. 4 shows inhibition of IL1Ra production by Tosyl. The effect of Tosyl on IL-1Ra production (mean \pm S.E.) by PBMC from 9 healthy individuals in 10% autologous sera cultured in microtiter plates pre-coated with A) HSA, and B) HSA/IgG.

FIG. 5 shows IL-2 induced proliferation in healthy individuals and RCC patients. IL-2 induced proliferation (mean \pm S.D.) by PBMC from normal healthy individuals (grey bars, 21-29 individuals) and PBMC from RCC patients (black bars, 12-18 individuals) cultured in 10% autologous sera on uncoated and pre-coated microtiter plates. Significant ($p=0.011$) difference in proliferation between PBMC from healthy individuals and RCC patients on uncoated plates, but not on HSA coated or on HSA/IgG coated plates. Significant ($p=0.0045$) difference in proliferation between PBMC from RCC patients cultured on uncoated and HSA/IgG coated plates.

FIG. 6 shows normal PBMC cultured in autologous sera (black bars) or sera from cancer patients (open bars) in the presence of IL-2. Proliferation was measured by ³H-uptake on day 7. Patients 88 and 124 had previously been shown to induce high levels of IL-6 production, whereas patient 112 did not.

FIG. 7 shows tumour biopsies stained for the presence of tissue bound IgG/IC and T-lymphocytes using a double staining technique with recombinant protein G (not binding to albumin). Different staining patterns are shown, viz. A) staining of vascular areas/endothelial cells and some lymphocytes for IgG. Some lymphocytes are not stained for IgG/IC. Low numbers of tumour infiltrating mononuclear cells, B) a diffuse staining of the tumour tissue for IgG/IC, whereby the majority of the lymphocytes are not stained for IgG/IC, C) staining tumour infiltrating macrophages

and some lymphocytes for IgG/IC, but tumour cells are generally negative, D) extensive staining of vascular areas for IgG/IC with very low numbers of infiltrating mononuclear cells.

- 5 **FIG. 8** shows cytopins of PBMC from two patients with malignant melanoma stained for the presence of IgG/IC, using recombinant protein-G (A) or monoclonal directed against the Fc-part of IgG.

- 10 **FIG. 9** shows IL-6 production by PBMCs from different subsets of colorectal cancer patients. A) without LPS stimulation and B) with LPS-stimulation.

- 15 **FIG. 10** shows survival in renal cell carcinoma patients according to IL-6 production by PBMCs in short term cultures where the microtitre plates were coated with HSA. High production is >2500 pg/ml.

- FIG. 11** shows inhibition of IL-6 production by IgG. Production of IL-6 by control PBMCs after culture on uncoated tissue culture wells (n = 37), HSA-coated (n = 37), or wells coated with HSA/IgG (n = 36).

- 20 **FIG. 12** shows the effect of chlorambucil on PHA-induced proliferation of PBL from RCC patients before treatment with IL-2. Modulation Index (MI) was calculated as described under Materials and Methods. The assays were performed at the following time points: 1) before start of treatment, 2) one week later, 48 hours after five days of IL-2 treatment, 3) after one week without IL-2 administration and 4) after an
25 additional week, 48 hours after another five days of IL-2 treatment combined with chlorambucil.

- FIG. 13** shows the effect of chlorambucil (CHL) on TNF- α production and proliferation of PHA-stimulated PBMC from RCC patients. PBMC were cultured with PHA in the
30 presence or absence of CHL for 72 hours and the cellular ^3H -uptake and the TN- α concentration in cell-free culture supernatants were assessed. Modulation Index was calculated as described under Materials and Methods. Each circle represents one patient.

- 35 **Fig. 14.** 2D gel electrophoresis of PBMC-adsorbed and unadsorbed urine fractions pooled from two patients with renal cell carcinoma. 230 μg of protein was loaded per 2D gel. Separated proteins (based on isoelectric focusing in the first dimension and molecular mass in the second dimension) were detected by SYPRO Ruby staining.

Fig. 15. 2D gel electrophoresis of PBMC-adsorbed and unadsorbed urine fractions from a patient with malignant melanoma. 350 ug of protein was loaded per 2D gel. Separated proteins (based on isoelectric focusing in the first dimension and molecular mass in the second dimension) were detected by SYPRO Ruby staining.

Fig. 16. Generation of IL-6 inducing factors by incubation of IgG (A and C) and albumin (B and D) with MMPs. Two experiments using different buffer systems are shown (as described in Material and Methods). The substrates were incubated with MMPs for 20 hours in experiments A, B, C and for 5 hours in experiment D. The production of IL-6 was then tested in cultures of PBMCs from healthy controls.

Fig. 17. Effect of collagen/collagen fragments on the proliferative response (measured as incorporation of ^3H -TdR) of normal PBMCs to IL-2. As can be seen a strong inhibitory effect was demonstrated in two out of three experiments.

Fig. 18. Modulation of IL-6 inducing factors by incubation of homogenised, washed tumour tissue with MMP-2. A and B represent two separate experiments with two different tumour tissues in each. The effect of this enzyme varies, dependent on the intra-tumoural milieu of different tumours, but it is clearly shown that MMP-2 has a modulatory effect on the production of IL-6 inducing factor / activity, which was tested in cultures of PBMCs from healthy controls.

Fig. 19. Generation of IL-6 inducing factors / activity by incubation of IgG and albumin with homogenised, washed tumour tissue. A and B represent two separate experiments. As shown in these two experiments adding IgG and in particular albumin to tumour tissue markedly increases the production of IL-6 inducing factor / activity, which was tested in cultures of PBMCs from healthy controls.

CLAIMS

1. Method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, including enzymes, is therapeutically controlled to minimise pathological production of such immunoregulatory substances being immunosuppressive, or to stimulate the production of such immunoregulatory substances being immunosupportive to enhance the performance status of the patient and/or to enhance the therapeutic control of a malignant tumour in a subject suffering from a cancer.
2. Method according to claim 1, wherein any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR modulation by administering a therapeutically effective amount of a FcR modulating agent.
3. Method according to claim 2, wherein any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR/Fc γ R modulation by administering a therapeutically effective amount of a FcR/Fc γ R blocking agent.
4. Method according to claims 2-3, wherein any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by therapeutically treating the patient to provide a FcR/Fc γ R modulation by administering a therapeutically effective amount of a FcR/Fc γ R cross-linking agent.
5. Method according to claims 2-4, wherein blocking or cross-linking of FcR is carried out using a therapeutically active amount of at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR.

6. Method according to claims 2-3, wherein at least one FcR-modulating substance minimising production of interleukin-1 receptor antagonist is administered in a therapeutically effective amount.
- 5 7. Method according to claims 2-3, wherein the modulation is carried out by blocking FcR by administering F(ab), or F(ab')₂-fragments.
8. Method according to one or more of the preceeding claims, wherein the modulating substance is a soluble receptor, fragment, peptide or synthetic construct
10 directed to the Fc-part of immunoglobulins.
9. Method according to claim 1, wherein FcγR I, FcγR II and/or FcγR III is modulated to stimulate IL-2 stimulation of clonal expansion of lymphocytes.
- 15 10. Method according to claims 1, wherein any compound blocking the production or biological activity of a factor inducing pathological production of any dys-regulatory mechanism of immunoregulatory substances, including one or more cytokines, including IL-1β, IL-1Ra, IL-6, IL-10, IL-17, TNF-α, and others, including enzymes, production, is administered in a therapeutically effective amount.
- 20 11. Method according to claim 10, wherein the blocking compound is a receptor blocking compound.
12. Method according to claim 10, wherein the blocking compound is a monoclonal
25 antibody, fragments thereof, peptides or synthetic constructs.
13. Method according to one or more of the preceding claims, wherein a compound having the ability of Inhibiting the production, activation or activity of enzymes generating Immunomodulatory fragments is administered in a therapeutically
30 effective amount.
14. Method according to claim 13, wherein the inhibiting compound is a monoclonal antibody, an anti-integrin antibody, peptides and / or synthetic constructs.
- 35 15. Method according to one or more of the preceding claims, wherein the modulating substance is an enzyme inhibitor.

16. Method according to one or more of the preceding claims, wherein the inhibiting compound is a matrix metalloproteinase inhibitor.

5 17. Method according to claim 10, wherein any compound blocking the factor inducing IL-6 production is administered in a therapeutically effective amount.

18. Method according to claim 10, wherein any compound blocking the factor inducing IL-1 β production is administered in a therapeutically effective amount.

10 19. Method according to claim 10, wherein any compound blocking the factor inducing IL-10 production is administered in a therapeutically effective amount.

20. Method according to claim 10, wherein any compound blocking the factor inducing TNF- α production is administered in a therapeutically effective amount.

15 21. Method according to claim 10, wherein any compound blocking the factor inducing IL-1Ra production is administered in a therapeutically effective amount.

20 22. Method according to claim 10, wherein monoclonal antibodies directed to enzymes generating immuno-modulatory fragments are administered in a therapeutically effective amount.

23. Method according to claim 10, wherein at least one anti-integrin antibody, peptide or construct is administered in a therapeutically effective amount.

25 24. Method according to claims 1-23, for treating cancer by administering a therapeutically active amount of compound to a person suffering from a cancer, which compound inhibits the production and / or biological activity of at least one factor of importance for
30 the performance status of a patient suffering from cancer,
immune mediated anti-tumour reactivity of a patient suffering from cancer,
systemic protection of metastatic disease of a patient suffering from cancer and
response to treatment including immuno-, chemo-, bio- and radiotherapy of a patient
suffering from cancer.

35 25. Method according to claim 24, wherein the fragment to be inhibited is extra cellular matrix derived fragment matrix, including fragments of collagen, fibronectin and laminin

26. Method according to claim 24, wherein the fragment to be inhibited is a serum protein fragment.
27. Method according to claim 26, wherein the fragment to be inhibited is a serum albumin derived fragment.
28. Method according to claim 26, wherein the fragment to be inhibited is an immunoglobulin derived fragment.
29. Method according to claim 26, wherein the fragment to be inhibited is a fibrinogen derived fragment.
30. Method according to claims 24-29, wherein a matrixmetalloprotease inhibitor having the ability of inhibiting the proteolytic effect of matrixmetalloproteases in forming a tissue factor of cancer.
31. Method according to claim 30, wherein the inhibitor has the ability of inhibiting the proteolytic effect of one or more of the matrixmetalloproteases , including the group of MMP-1, MMP -2, MMP -3, MMP-7, MMP-13.
32. Method for analysing the amount and/or certain pattern of dys-regulatory mechanism substances, including their mRNA, including any inducing factor, inducing the production of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, whereby the amount of such dys-regulatory mechanism substances is determined in a tissue sample, whereby the prognosis of a subject suffering from cancer can be determined and/or the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored.
33. Method according to claim 32, wherein tissue is whole blood, serum, plasma, lymphatic fluid, saliva, urine, faeces, ascites, pleural effusion, pus, as well as any tissue, including inflammatory cells.
34. Method according to claims 32-33, wherein any compound having the ability of inhibiting the production, activation or activity of enzymes generating fragments of intra-tumoural tissue are determined.

35. Method according to claims 32-34, wherein any fragment or new epitopes generated by the activity of intratumoural enzymes is determined in any tissue from a cancer patient.
- 5 36. Method according to claims 34-35, wherein the activity of any compound having the ability of inhibiting the production, activation or activity of enzymes generating fragments is monitored by determining these fragments or new epitopes exposed by the enzymatic activity in any tissue from a cancer patient.
- 10 37. Method according to claim 36, wherein the inhibiting compound is a matrixmetalloproteinase inhibitor.
38. Method according to claims 32-33, wherein any compound blocking production or biological activity of a factor inducing pathological production of any dys-regulatory
15 mechanism of immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others including enzymes, production, is determined.
39. Method according to claims 32-33, wherein the amount of any inducing factor or
20 mRNA thereof inducing the production of immunoregulatory substances, including one or more cytokines including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α and others, found in tissue, is determined by determining the production of immunoregulatory substances, including cytokines, including IL-1Ra, IL-6, IL-1 β and/or TNF- α and others produced by PBMC after exposure to these factors.
- 25 40. Method according to claims 32-33, wherein samples are obtained in a way, including tubes and syringes, not binding or inactivating immunoregulatory substances, including inducing factors.
- 30 41. Method according to claims 32-33, wherein the amount of any inducing factor inducing the production of immunoregulatory substances, including one or more cytokines including including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is determined directly.
- 35 42. Method according to claims 32-33, wherein the amount / occurrence of any cell bound factor inducing the production of immunoregulatory substances, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is determined.

43. Method according to claims 32-33, wherein the amount of any urine present inducing factor inducing the production of immunoregulatory substances, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, is determined by using an urine dip stick containing binding substance/s binding said inducing factor and/or colour developing reagents to said inducing factor.
44. Method according to claims 32-33, wherein the amount of cell bound immune complexes, CBIC, is determined.
45. Method according to claims 32-33, wherein peripheral blood mononuclear cells PBMC being positive for any immunoglobulin staining are determined.
46. Method according to claims 32-33, wherein IL-1Ra is determined.
47. Method according to claims 32-33, wherein down-regulation of CD28 on CD4+ and/or CD8+ lymphocytes is determined.
48. Method according to claims 32-33, wherein down-regulation of CD80 and/or CD86 is determined.
49. Method according to claims 32-33, wherein determination of any other modulation of other immunoregulatory substances is made.
50. Method according to claims 32-49, wherein the content of IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , is determined by using an assay, to determine the amount of an inducing factor inducing IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, activity.
51. Method according to claim 50, wherein the assay utilises any tissue and the determinations are made using any immuno-cyto-histochemical method, as electrophoresis, chromatography, any immunoassay including, ELISA, Elispot, RIA and others any blotting technique, including Western blotting, Southern blotting and others, any bioassay, any tissue culture technique, RT-PCR, flow cytometry, cytometric bead array, DNA microarray and / or proteomics.
52. Method according to one or more of claims 32-33, wherein dys-regulatory mechanism substances in tissue from cancer patients, which substances suppress the

immune mediated systemic protection resulting in establishment of micrometastases, are identified.

5 53. Method according to claim 44, wherein patients suffering from potential risk are candidates for adjuvant treatment.

10 54. Method according to claims 32-53 for diagnosing of presence/absence of cancer by identifying pathological immunoregulatory substances in cancer and diagnosis of cancer related / tumour derived tissue factor of importance for a cancer patient's performance status, immune mediated anti-tumour reactivity, systemic protection of metastatic disease of a patient suffering from cancer and response to treatment including immuno-, chemo-, bio- and radiotherapy.

15 55. Diagnosis according to claim 54, wherein said factor is present in tumour tissue and body fluids.

20 56. Diagnosis according to claim 54, wherein said factor has the ability of inducing cytokines or other immunoregulatory substances.

57. Diagnosis according to claim 54, wherein said factor directly or indirectly has the ability of inducing production of proteolytic enzymes by tumour cells or inflammatory cells.

25 58. Diagnosis according to claim 54, wherein said factor is a fragment of extra cellular matrix, including collagen, fibronectin and laminin

30 59. Diagnosis according to claim 54, wherein said factor is a fragment of at least one serum protein.

60. Diagnosis according to claim 54, wherein said factor is a fragment of serum albumin.

35 61. Diagnosis according to claim 54, wherein said factor is a fragment of at least one immunoglobulin.

62. Diagnosis according to claim 54, wherein said factor is a fragment of fibrinogen

63. Kit for quantitative and/or qualitative analysis of amount of and/or certain pattern of dys-regulatory factor and/or factors inducing the production and/or activation of immunoregulatory substances, whereby prognosis of cancer can be determined and the therapeutic efficacy of any anti-cancer treatment can be predicted and monitored, comprising an indicator for the presence of said dys-regulatory factor/s including inducing factor/s.
64. Kit according to claim 63, wherein the kit comprises an indicator for the presence of any factor inducing immunoregulatory substances, including cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , and others, activity.
65. Kit according to claims 63-64, wherein the kit comprises a nutrient for peripheral blood mononuclear cells and a determinant for inducing factor for inducing immunoregulatory substances including inducing factors of IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others.
66. Kit according to claim 63, wherein it comprises a urine dip stick comprising binding substance/s and/or colour developing reagents.
67. Kit according to claim 63, wherein the kit comprises determinants for enzymatic degradation products of tumour substances / extra cellular matrix, ECM.
68. Kit according to claim 67, wherein a matrix metalloproteinaseinhibitor is monitored.
69. Kit according to claim 63, wherein the kit comprises a determinant for dys-regulatory substances in tissue from cancer patients, which substances suppress the immune mediated systemic protection resulting in the establishment of micrometastases.
70. Kit according to claim 63, wherein the amount of cell bound immune complexes, CBIC, is determined.
71. The use of at least one regulatory mechanism controlling factor of at least one immunoregulatory substance, including inducing factor of the production or biological activity of immunoregulatory substances including cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, including enzymes, for the production of a pharmaceutical preparation to be used for therapeutic control and for minimisation of

pathological production of immunosuppressive immunoregulatory substances, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , and others, including enzymes or to stimulate production of immunosupportive immunoregulatory substances in a patient suffering from a cancer and to enhance the efficacy and/or possibility of therapeutic treatment of cancer or modulation of dys-regulatory factors to enhance performance status.

72. Use according to claim 71, wherein a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, and/or TNF- α , and others, production in a patient suffering from cancer by therapeutically modulating FcR activity.

73. Use according to claim 71-72, wherein a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/Fc γ R activity.

74. Use according to claim 71-72, wherein a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, production in a patient suffering from cancer is modulated by cross-linking FcR/Fc γ R activity.

75. Use according to claims 71-72, wherein at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR cross-linking.

76. Use according to claim 75, wherein an agent modulating Fc γ R I, Fc γ R II and/or Fc γ R III used to stimulate IL-2 stimulation of clonal expansion of lymphocytes is used in the manufacture of a pharmaceutical preparation.

77. Use according to claim 75, wherein FcR antibodies or fragments of FcR antibodies directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking cross-linking of FcR.

78. Use according to claim 77, wherein anti-FcγR I, FcγR II and/or FcγR III antibodies is used in the manufacture of a pharmaceutical preparation for blocking of FcγR.

5 79. Use according to claim 77, wherein a compound being able to down-regulate the expression of FcR is used in the manufacture of a pharmaceutical preparation for down-regulating FcR.

80. Use according to claim 77, wherein at least one FcR-blocking substance
10 minimising production of interleukin-1 receptor antagonist is used in the manufacture of a pharmaceutical preparation for blocking the activity of interleukin-1.

81. Use according to claim 77, wherein at least one FcR-modulating soluble receptor, fragment, peptide or synthetic construct directed to the Fc-part of immunoglobulins
15 is used in the manufacture of a pharmaceutical preparation.

82. Use according to claim 77, wherein at least one FcR-modulating enzyme inhibitor is used in the manufacture of a pharmaceutical preparation.

20 83. Use according to claim 77, wherein at least one FcR-inhibiting matrix metalloproteinase inhibitor is used in the manufacture of a pharmaceutical preparation.

84. Use according to claim 71, wherein any compound including any enzymes,
25 blocking production or biological activity of any factor inducing pathological production of one or more cytokines is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokines.

85. Use according to claim 84, wherein any factor inducing IL-6 production is used in
30 the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

86. Use according to claim 84, wherein any factor inducing IL-1β production is used
35 in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

87. Use according to claim 84, wherein any factor inducing IL-10 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

5 88. Use according to claim 84, wherein any factor inducing IL-17 production is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

89. Use according to claim 84, wherein any factor inducing TNF- α production is used
10 in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

90. Use according to claim 84, wherein any factor inducing IL-1Ra production is used
15 in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokine.

91. Use according to claim 71, wherein a compound having the ability of inhibiting
the activation and/or activity of enzymes generating immunomodulatory fragments is
used in the manufacture of a pharmaceutical preparation for inhibiting the activation
20 or activity of enzymes generating immunomodulatory fragments.

92. Use according to claim 71, wherein antibodies directed to enzymes generating
immuno-modulatory fragments are used in the manufacture of a pharmaceutical
25 preparation.

93. Use according to claim 71, wherein at least one monoclonal antibody, anti-
integrin antibody, peptide and/or synthetic construct thereof is used in the
manufacture of a pharmaceutical preparation.

30 94. A pharmaceutical composition comprising a regulatory mechanism controlling
factor of an inducing factor of the production or biological activity of
immunoregulatory substances including one or more cytokines, for the production of
a pharmaceutical preparation to be used for therapeutically control and minimise
pathological production of immunosuppressive immunoregulatory substances including
35 one or more cytokine, or to stimulate production of an immunosupportive
immunoregulatory substance in a patient suffering from a cancer to enhance the
efficacy and/or possibility of therapeutic treatment of cancer, optionally in
combination with therapeutically inert additive to enhance performance status.

95. Pharmaceutical composition according to claim 94, wherein a FcR modulating agent is present in a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokine production in a patient suffering from cancer by therapeutically modulating FcR activity.

96. Pharmaceutical composition according to claim 95, wherein a FcR modulating agent is used in the manufacture of a pharmaceutical preparation for controlling immunoregulatory substances, including one or more cytokines, including IL-1 β , IL-1Ra, IL-6, IL-10, IL-17, TNF- α , and others, including enzymes, production in a patient suffering from cancer is modulated by therapeutically blocking FcR/Fc γ R activity.

97. Pharmaceutical composition according to claim 95, wherein at least one immunoglobulin, FcR antibodies or fragments of antibodies or synthetic constructs including peptides directed to FcR is used in the manufacture of a pharmaceutical preparation for blocking or cross-linking FcR activity.

98. Pharmaceutical composition according to claim 97, wherein an agent modulating Fc γ R I, Fc γ R II and/or Fc γ R III is present to stimulate IL-2 stimulation of clonal expansion of lymphocytes.

99. Pharmaceutical composition according to claim 97, wherein anti-Fc γ R I antibodies is present in a pharmaceutical preparation for blocking of Fc γ R.

100. Pharmaceutical composition according to claim 97, wherein a compound being able to down-regulate the expression of FcR is present in the pharmaceutical preparation for down-regulating FcR.

101. Pharmaceutical composition according to claim 97, wherein at least one FcR-blocking substance minimising production of interleukin-1 receptor antagonist is present in the pharmaceutical preparation for blocking the activity of interleukin-1.

102. Pharmaceutical composition according to claim 97, wherein at least one FcR-modulating soluble receptor is used.

103. Pharmaceutical composition according to claim 97, wherein at least one FcR-modulating enzyme inhibitor is used.

104. Pharmaceutical composition according to claim 97, wherein at least one FcR-inhibiting enzyme inhibitor is used.
- 5 105. Pharmaceutical composition according to claim 97, wherein any compound blocking production or biological activity of any factor inducing pathological production of one or more cytokines is used in the manufacture of a pharmaceutical preparation for blocking a factor inducing pathological production of such cytokines.
- 10 106. Pharmaceutical composition according to claim 94, wherein a compound having the ability of inhibiting the production, activation of enzymes generating immunomodulatory fragments is present in the pharmaceutical preparation for inhibiting the activation of enzymes generating immunomodulatory fragments.
- 15 107. Pharmaceutical composition according to claim 94, wherein any factor inducing IL-6 production is used.
108. Pharmaceutical composition according to claim 94, wherein any factor inducing IL-1 β production is used.
- 20 109. Pharmaceutical composition according to claim 94, wherein any factor inducing IL-10 production is used.
110. Pharmaceutical composition according to claim 94, wherein any factor inducing IL-17 production is used.
- 25 111. Pharmaceutical composition according to claim 94, wherein any factor inducing TNF- α production is used.
- 30 112. Pharmaceutical composition according to claim 94, wherein any factor inducing IL-1Ra production is used in the manufacture of a pharmaceutical preparation.
113. Pharmaceutical composition according to claim 94, wherein a compound blocking a factor inducing pathological production of immunoregulatory substances, including one or more cytokine production is present in the pharmaceutical preparation for blocking a factor inducing pathological production of such immunoregulatory substances.
- 35

114. Pharmaceutical composition according to claim 94, wherein antibodies directed to enzymes generating immuno-modulatory fragments are present.

5 115. Pharmaceutical composition according to claim 94, wherein at least one monoclonal antibody, anti-integrin antibody, peptide and/or synthetic construct thereof, is used.

10 116. Cancer related / tumour derived tissue factor of importance for a cancer patient's performance status, immune mediated anti-tumour reactivity, systemic protection of metastatic disease of a patient suffering from cancer and response to treatment including immuno-, chemo-, bio- and radiotherapy.

15 117. Factor according to claim 116, wherein said factor is present in tumour tissue and body fluids.

20 118. Factor according to claim 116, wherein said factor has the ability of inducing cytokines or other immunoregulatory substances.

119. Factor according to claim 116, wherein said factor directly or indirectly has the ability of inducing production of proteolytic enzymes by tumour cells or inflammatory cells.

25 120. Factor according to claim 116, wherein said factor is a fragment of extra cellular matrix, including collagen, fibronectin and laminin

30 121. Factor according to claim 116, wherein said factor is a fragment of at least one serum protein.

122. Factor according to claim 121, wherein said factor is a fragment of serum albumin.

35 123. Factor according to claim 121, wherein said factor is a fragment of at least one immunoglobulin.

124. Factor according to claim 121, wherein said factor is a fragment of fibrinogen.





FIG. 1

2/22




FIG.2

3/22




FIG.3

4/22




FIG. 4




FIG. 5

6/22




FIG. 6

7/22




FIG.6cont.

8/22




FIG. 6cont.




FIG. 7





FIG. 8

11/22




FIG.9

12/22




FIG. 10




FIG. 11

14/22




FIG. 12




FIG. 13

16/22

Pooled urine fraction (3-30 kD) from two patients with renal cell carcinoma




FIG. 14

Urine fraction (3-30 kD) from patient with malignant melanoma.




FIG. 15

18/22




FIG. 16

19/22





FIG. 16cont.

20/22




FIG. 17

21/22




FIG. 18

22/22





FIG. 19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00869

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 38/00, A61K 39/00 // C07K 15/52, C07K 14/735, C07K 16/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, MEDLINE, BIOSIS, EMBASE, EPO-INTERNAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03028630 A2 (WYETH), 10 April 2003 (10.04.03), abstract	32-124
	--	
X	WO 0226833 A1 (UNIVERSITY OF TENNESSEE CORPORATION), 4 April 2002 (04.04.02), page 1, line 5 - page 2, line 2, abstract	32-124
	--	
X	WO 0015214 A1 (ILEXUS PTY LIMITED), 23 March 2000 (23.03.00), page 21, line 21 - line 28	32-124
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

~~"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone~~

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

9 Sept. 2003

Date of mailing of the international search report

10 -09- 2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen/Els

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00869

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BIOSIS, accession no. PREV200000385924, Muramatsu Takashi et al: "Analysis of circulating plasma matrix metalloproteinases (MMP) and tissue inhibitors of MMP in lung cancer patients", Nichidai Igaku Zasshi, (2000), vol. 59, no. 3, pages 97-102</p> <p>--</p>	32-71,91,94, 106,114
X	<p>Intern. Rev. Immunol. Vol. 16, Hélène Rouard et al: "Fc Receptors as Targets for Immunotherapy", pages 147-185, pages 150-158</p> <p>--</p>	32-124
X	<p>DATABASE WPI Week 198709 Derwent Publications Ltd., London, GB; Class A61K, AN 1987-061183 & JP 62016430 A (AJINOMOTO KK), 24 Januari 1987 (1987-01-24) abstract</p> <p>--</p>	32-124
X	<p>Gene Therapy, vol. 8, 2000, N. Gruel et al: Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FCyR scFv on cancer cell surface", pages 1721-1728</p> <p>--</p>	32-124
X	<p>Journal of Immunotherapy, vol. 22, 1999, Daniela Piantatelli et al: "Local Expression of Cytokines in Human Colorectal Carcinoma: Evidence of Specific Interleukin-6 Gene Expression", pages 25-32</p> <p>--</p>	32-124
X	<p>Annals of Oncology, vol. 12, 2001, W. Ruka et al: "Alterations of routine blood testes in adult patients with soft tissue sarcomas: Relationships to cytokine serum levels and prognostic significance, pages 1423-1432</p> <p>--</p>	32-124

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00869

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	The Journal of Biological Chemistry, vol. 269, no. 39, 1994, 09, Patrick T. Harrison et al: "Binding of Monomeric Immunoglobulin G Triggers FcγRI-mediated Endocytosis", pages 24396-24402 --	32-124
A	Journal of Immunology, vol. 141, 1988, 08, Joop M.H. Debets et al: "Fc-Receptor Cross- Linking Induces Rapid Secretion of Tumor Necrosis Factor (Cachectin) by Human Peripheral Blood Monocytes", pages 1197-1201 --	32-124
A	Journal of Immunological Methods, vol. 248, 2001, Paul K. Wallace et al: "Bispecific antibody- targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo", pages 167-182 -- -----	32-124

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/00869

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-31
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 1-31 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human animal body (Rule 39.1)).
2. ☒ Claims Nos.: 32-124
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next page
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/00869

Present claims 32-124 relate to the use of an indefinite number of inducing factors and a very large number of immunoregulatory substances and many different methods for determining these substances. It also contains a large number of ways of blocking dys-regulatory factors. Thus, the claims do not disclose the invention in a sufficiently clear manner. In fact, the claims contain so many different possibilities that a lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible (See Art 17(2)(a)).

The breath of the claims should be such that it represents a reasonable generalisation of the examples provided, and such that it is credible that every compound falling within the scope actually provides a solution to the problem underlying the invention. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is not to be found for the present claims.

The application also lacks clarity and conciseness due to the large number of claims.

Consequently, the search has been carried out only for those parts of the claims 32-124 which do appear to be clear and concise namely the analyses of inducing factors of cytokines for prognosis of a subject suffering from cancer and suppression of said inducing factors in cancer patients by blocking or cross-linking the Fc-receptor

INTERNATIONAL SEARCH REPORT
Information on patent family members

26/07/03

International application No.
PCT/SE 03/00869

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	03028630	A2	10/04/03	US	2003049798 A	13/03/03
				US	2003108549 A	12/06/03

WO	0226833	A1	04/04/02	NONE		

WO	0015214	A1	23/03/00	AU	5755499 A	03/04/00
				CA	2343414 A	23/03/00
				CN	1323203 T	21/11/01
				EP	1109545 A	27/06/01
				JP	2002524504 T	06/08/02
				US	6050266 A	18/04/00
				US	6315717 B	13/11/01
				US	6355683 B	12/03/02
				US	2002040182 A	04/04/02
				US	2002061844 A	23/05/02
